

## Refine Search

### Search Results -

Term	Documents
@PY	35080757
(23 AND (@PY < "1986")).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	0
(L23 AND @PY<1986 ).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	0

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L24

Refine Search

Recall Text

Clear

Interrupt

### Search History

DATE: Thursday, May 19, 2005    [Printable Copy](#)    [Create Case](#)

Set Name	Query	Hit Count	Set Name
side by side			result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>			
<u>L24</u>	L23 and @py<1986	0	<u>L24</u>
<u>L23</u>	Factor VIII light chains same heavy chain	40	<u>L23</u>
<u>L22</u>	L19 and A domain and C domain	0	<u>L22</u>
<u>L21</u>	L20 and domain	0	<u>L21</u>
<u>L20</u>	L19 and A and C	18	<u>L20</u>
<u>L19</u>	L18 and @py<1986	18	<u>L19</u>
<u>L18</u>	human Factor VIII	738	<u>L18</u>
<u>L17</u>	L8 and @py<1986	0	<u>L17</u>
<u>L16</u>	L9 and @py<1986	0	<u>L16</u>
<u>L15</u>	L10 and @py<1986	0	<u>L15</u>
<u>L14</u>	L9 and py<1986	241	<u>L14</u>

<u>L13</u>	L12 and @py<1986	0	<u>L13</u>
<u>L12</u>	L11 and L10	227	<u>L12</u>
<u>L11</u>	L9 and plasmid	227	<u>L11</u>
<u>L10</u>	L9 and vector	236	<u>L10</u>
<u>L9</u>	L8 and polynucleotide	241	<u>L9</u>
<u>L8</u>	Factor VIII same polypeptide same express\$	425	<u>L8</u>
<u>L7</u>	Factor VIIi ame polypeptide same express\$	0	<u>L7</u>
<u>L6</u>	L5 and @py<1986	5	<u>L6</u>
<u>L5</u>	L4 and expression	3349	<u>L5</u>
<u>L4</u>	L3 and plasmid	3452	<u>L4</u>
<u>L3</u>	L2 and A and C	7011	<u>L3</u>
<u>L2</u>	Factor VIII	7736	<u>L2</u>
<u>L1</u>	US 4868112	3	<u>L1</u>

END OF SEARCH HISTORY

FILE 'PROMT' ENTERED AT 14:11:35 ON 19 MAY 2005  
COPYRIGHT (C) 2005 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 14:11:35 ON 19 MAY 2005  
COPYRIGHT (C) 2005 Prous Science

FILE 'PS' ENTERED AT 14:11:35 ON 19 MAY 2005  
COPYRIGHT (C) 2005 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 14:11:35 ON 19 MAY 2005  
COPYRIGHT (C) 2005 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 14:11:35 ON 19 MAY 2005  
Copyright (c) 2005 The Thomson Corporation

FILE 'SYNTHLINE' ENTERED AT 14:11:35 ON 19 MAY 2005  
COPYRIGHT (C) 2005 Prous Science

FILE 'TOXCENTER' ENTERED AT 14:11:35 ON 19 MAY 2005  
COPYRIGHT (C) 2005 ACS

FILE 'USPATFULL' ENTERED AT 14:11:35 ON 19 MAY 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:11:35 ON 19 MAY 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 14:11:35 ON 19 MAY 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 14:11:35 ON 19 MAY 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 14:11:35 ON 19 MAY 2005  
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 14:11:35 ON 19 MAY 2005  
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 14:11:35 ON 19 MAY 2005  
COPYRIGHT (C) 2005 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s Factor VIII

25 FILES SEARCHED...

31 FILES SEARCHED...

54 FILES SEARCHED...

L1 107562 FACTOR VIII

=> s domain A and domain C

13 FILES SEARCHED...

22 FILES SEARCHED...

25 FILES SEARCHED...

32 FILES SEARCHED...

50 FILES SEARCHED...

62 FILES SEARCHED...

66 FILES SEARCHED...

69 FILES SEARCHED...

L2 2583 DOMAIN A AND DOMAIN C

=> s L1 and L2

56 FILES SEARCHED...

L3 60 L1 AND L2

```

=> s vector
SYSTEM LIMITS EXCEEDED - SEARCH ENDED
  38 FILES SEARCHED...
The search profile you entered was too complex or gave too many
answers. Simplify or subdivide the query and try again. If you have
exceeded the answer limit, enter DELETE HISTORY at an arrow prompt
(=>) to remove all previous answers sets and begin at L1. Use the
SAVE command to store any important profiles or answer sets before
using DELETE HISTORY.

=> s L3 and vector
  47 FILES SEARCHED...
L4          44 L3 AND VECTOR

=> s L4 and express
=> s l4 and express?
  24 FILES SEARCHED...
  25 FILES SEARCHED...
  46 FILES SEARCHED...
  63 FILES SEARCHED...
L5          44 L4 AND EXPRESS?

=> d L5

L5      ANSWER 1 OF 44  BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
AN      1997-03702  BIOTECHDS
TI      New Factor-VIII:c analogs;
        protein engineering with a Factor-V A- and/or C-domain, for increased
        half-life and/or specific activity; use in hemophilia-A therapy and
        gene therapy
AU      Hung D T
PA      Chiron
LO      Emeryville, CA, USA.
PI      WO 9703191 30 Jan 1997
AI      WO 1996-US11013 28 Jun 1996
PRAI    US 1995-1030 11 Jul 1995
DT      Patent
LA      English
OS      WPI: 1997-119047 [11]

=> d L5 2-44 ibib,abs

L5      ANSWER 2 OF 44  IFIPAT  COPYRIGHT 2005 IFI on STN
AN      10376644  IFIPAT;IFIUDB;IFICDB
TITLE:   COMPOSITIONS AND METHODS OF USE OF MAMMALIAN
        RETROTRANSPOSONS
INVENTOR(S) : DeBerardinis; Ralph, Philadelphia, PA, US
              Kazazian; Haig H. JR., Baltimore, MD, US
              Ostertag; Eric, Philadelphia, PA, US
PATENT ASSIGNEE(S) : The Trustees Of The University Of Pennsylvania, US
AGENT:    MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,
          PHILADELPHIA, PA, 19103-2921, US

              NUMBER          PK      DATE
              -----
PATENT INFORMATION:  US 2003121063      A1    20030626
APPLICATION INFORMATION: US 2002-216122      20020809

              APPLN. NUMBER          DATE          GRANTED PATENT NO.
              -----
CONTINUATION-IN-PART OF:  US 1996-749805      19961115

```

CONTINUATION-IN-PART OF: US 2000-653812 20000901  
DIVISION OF: US 1997-847844 19970428 6150160

	NUMBER	DATE
PRIORITY APPLN. INFO.:	US 1995-6831P	19951116 (Provisional)
FAMILY INFORMATION:	US 2003121063	20030626
	US 6150160	
DOCUMENT TYPE:	Utility	
	Patent Application - First Publication	
FILE SEGMENT:	CHEMICAL	
	APPLICATION	
OTHER SOURCE:	CA 139:48143	

GOVERNMENT INTEREST:

(0002) This invention was supported in part by funds from the U. S. Government (NIH Grant Nos. GM45398, GM36481 and CA16519) and the U.S. Government may therefore have certain rights in the invention.

PARENT CASE DATA:

This application is a continuation-in-part application of copending U.S. patent application Ser. No. 09/653,812, filed Sep. 1, 2000, which is a divisional of U.S. application Ser. No. 08/ 847,844, filed Apr. 28, 1997, now U.S. Pat. No. 6,150,160, which is a continuation-in-part of U.S. patent application Ser. No. 08/749,805, filed on Nov. 15, 1996, now abandoned, which claims priority under 35 U.S.C. section 119(e) to U.S. Provisional Patent Application No. 60/006,831, filed on Nov. 16, 1995.

NUMBER OF CLAIMS: 22 26 Figure(s).

DESCRIPTION OF FIGURES:

FIG. 1 comprises FIGS. 1A through 1B. FIG. 1A is a diagram depicting the organization of a 6.0 kb human L1 element. ORF1 and ORF2 are indicated by dark rectangles; the 5' and 3' untranslated regions are indicated by shaded rectangles and the untranslated region between ORF1 and ORF2 is indicated by a white stripe. The approximate position of the endonuclease (EN), reverse transcriptase (RT), cysteine-rich C. motif and poly A tail (AAAAA)n are indicated. Arrows indicate the target site duplications which flank the element. FIG. 1B is a diagram of an overview of a retrotransposition assay. The element L1.2 was tagged with an indicator gene (mneoI) containing an antisense copy of the neo gene disrupted by intron 2 of the gamma-globin gene in the sense orientation. The splice donor (SD) and splice acceptor (SA) sites of the intron are indicated on the figure. The neo gene is also flanked by a heterologous promoter (P') and a polyadenylation signal (A') denoted by the striped triangles. Transcripts originating from the promoter driving L1.2mneoI \*\*\*expression\*\*\* (P) can splice the intron, but continue to contain an antisense copy of the neo gene. G418-resistant (G418R) colonies should arise only when this transcript is reverse transcribed, integrated into chromosomal DNA, and **expressed** from its own promoter, P'.

FIG. 2A is a diagram depicting cloning of L1.2mneoI. L1.2mneoI was cloned into pCEP4 to create pJM101. pCEP4 contains an origin of replication (Ori) and a selectable marker (Amp) for prokaryotic cells and an origin of replication and transacting factor (Ori/EBNA1) and a selectable marker (Hyg) for eukaryotic cells. The direction of transcription of each gene is denoted by arrows. The features of L1.2mneoI are described in the description of FIG. 1.

FIG. 2B, comprising FIGS. 2Bi through 2Biii, is a diagram depicting mutant constructs of L1.2mneoI. FIG. 2Bi depicts the construct pJM102, which lacks the 910 bp 5' UTR of L1.2; FIG. 2Bii depicts the construct pJM103, which has a 3.8 kb deletion wherein most of the 5' UTR, all of ORF1 and the first 2.1 kb of ORF2 are deleted; FIG. 2Biii depicts the construct pJM105, which contains a missense mutation (D702Y) in ORF2. Each of the mutants have the pCEP4 sequences as the **vector** portion.

FIG. 3A is a diagram outlining the L1.2mneoI retrotransposon assay. HeLa cells were transfected with the desired constructs using lipofectamine.

transgenic mice. Insertion #1 is 1.9 kb in length and contains an inversion of the 5' end with a 73 bp deletion at the inversion point. A 63-bp poly A tail is added after the SV40 poly A signal, and the insertion is flanked by 14 bp target site duplications (TSD), in uppercase letters. The flanking sequence is in lower case. FIG. 23B depicts an L1 insertion in a transgenic mouse. Insertion #2 is 4.3 kb in length. It contains a 92 bp poly A tail added after the SV40 poly A signal, and the insertion is flanked by 6-bp target site duplications. The L1 inserted into intron 1 of a predicted gene (mCG57584 Celera Discovery System) on chromosome 9.!

L5 ANSWER 3 OF 44 IFIPAT COPYRIGHT 2005 IFI on STN  
 AN 03506846 IFIPAT;IFIUDB;IFICDB  
 TITLE: PROTEIN COMPLEXES HAVING **FACTOR**  
**VIII:C** ACTIVITY AND PRODUCTION THEREOF;  
 NUCLEOTIDE SEQUENCES CODING ANTIHEMOPHILIC FACTOR;  
 FOR THE TREATMENT OF HEMOPHILIA  
 INVENTOR(S): Burke; Rae Lyn, San Francisco, CA  
 Chapman; Barbara, Berkeley, CA  
 Mikkelsen; Jan Moller, Gentofte, DK  
 Rasmussen; Mirella Ezban, Copenhagen, DK  
 PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA  
 Novo Nordisk A/S, Bagsvaerd, DK  
 PRIMARY EXAMINER: Low, Christopher S. F  
 ASSISTANT EXAMINER: Bugaisky, Gabriele E  
 AGENT: Blackburn, Robert P.  
 Guth, Joseph H.  
 Robins, Roberta L.

	NUMBER	PK	DATE
PATENT INFORMATION:	US 6228620	B1	20010508
APPLICATION INFORMATION:	US 1995-441943		19950516
EXPIRATION DATE:	8 May 2018		

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
CONTINUATION OF:	US 1991-652099	19910207	ABANDONED
CONTINUATION-IN-PART OF:	US 1986-822989	19860127	ABANDONED
CONTINUATION-IN-PART OF:	US 1987-51916	19870519	ABANDONED
DIVISION OF:	US 1993-161770	19931203	5595886
FAMILY INFORMATION:	US 6228620	20010508	
	US 5595886		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	CHEMICAL		
	GRANTED		

NUMBER OF CLAIMS: 91

AB Recombinant protein complexes having human **Factor VIII**  
 :C activity are **expressed** in a eukaryotic host cell by  
 transforming the host cell with first and second **expression**  
 cassettes encoding a first polypeptide substantially homologous to human  
**Factor VIII:C A domain** and a second  
 polypeptide substantially homologous to human **Factor**  
**VIII:C C domain**, respectively. In the present  
 invention, the first polypeptide may be extended having at its Cterminal  
 a human **Factor VIII:C B domain** N-terminal  
 peptide, a polypeptide spacer of 3-40 amino acids, and a human  
**Factor VIII:C B domain C-terminal**  
 peptide. **Expression** of the second polypeptide is improved by  
 employing an alpha1 -antitrypsin signal sequence.

CLMN 91

L5 ANSWER 4 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2005:105707 USPATFULL  
TITLE: Gene delivery to tumors  
INVENTOR(S): Sullivan, Sean M., Gainesville, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005090646	A1	20050428
APPLICATION INFO.:	US 2004-864774	A1	20040609 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-476941P	20030609 (60)
	US 2004-557030P	20040326 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AKERMAN SENTERFITT, P.O. BOX 3188, WEST PALM BEACH, FL, 33402-3188, US	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	3310	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods and compositions for gene therapy for tumors. Cytotoxic agents are selectively **expressed** in endothelial cells of tumor blood vessels, and delivered to tumor cells adjacent to the blood vessels, producing a bystander effect such that all the cells in contact with the transfected cells are killed or permanently growth arrested. In particular, cytotoxic gene products secreted from the transfected cell using a secretory signal sequence, include a membrane permeability domain at the N- or C-terminus that can shuttle the cytotoxic domain into non-transfected cells and back into transfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2005:105498 USPATFULL  
TITLE: Human tumor necrosis factor receptors TR21 and TR22  
INVENTOR(S): Zeng, Zhizhen, Lansdale, PA, UNITED STATES  
Ruben, Steven M., Brookeville, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005090436	A1	20050428
APPLICATION INFO.:	US 2003-620562	A1	20030717 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-910562, filed on 23 Jul 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US23124	20010723
	US 2000-220116P	20000724 (60)
	US 2000-221143P	20000727 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	

LINE COUNT: 9000

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to two novel proteins, TR21 and TR22, which are members of the tumor necrosis factor (TNF) receptor. In particular, isolated nucleic acid molecules are provided encoding the human TR21 and TR22 protein. TR21 and TR22 polypeptides are also provided as are **vectors**, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 and TR22 activity; and methods of treating immune disorders by administering TR21 and TR22 polynucleotides, polypeptides, agonists, and antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2005:104996 USPATFULL

TITLE: Novel proteins with targeted binding

INVENTOR(S): Kolkman, Joost, Voetweg 13, BELGIUM  
Stemmer, Willem P.C., Los Gatos, CA, UNITED STATES  
Freskgard, Per-Ola, Norrkoping, SWEDEN

PATENT ASSIGNEE(S): Avidia Research Institute, Mountain View, CA, UNITED STATES (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005089932	A1	20050428
APPLICATION INFO.:	US 2004-871602	A1	20040617 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2004-840723, filed on 5 May 2004, PENDING Continuation-in-part of Ser. No. US 2003-693056, filed on 24 Oct 2003, PENDING Continuation-in-part of Ser. No. US 2003-693057, filed on 24 Oct 2003, PENDING Continuation-in-part of Ser. No. US 2002-289660, filed on 6 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-133128, filed on 26 Apr 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-374107P	20020418 (60)
	US 2001-333359P	20011126 (60)
	US 2001-337209P	20011119 (60)
	US 2001-286823P	20010426 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	97	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	44 Drawing Page(s)	
LINE COUNT:	6019	

AB Methods for identifying discrete monomer domains and immuno-domains with a desired property are provided. Methods for generating multimers from two or more selected discrete monomer domains are also provided, along with methods for identifying multimers possessing a desired property. Presentation systems are also provided which present the discrete monomer and/or immuno-domains, selected monomer and/or immuno-domains, multimers and/or selected multimers to allow their selection. Compositions, libraries and cells that **express** one or more library member, along with kits and integrated systems, are also included in the present invention.

L5 ANSWER 7 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2005:87833 USPATFULL



TITLE: Methods and composition for delivering nucleic acids  
and/or proteins to the intestinal mucosa  
INVENTOR(S): Chen, Wei, San Diego, CA, UNITED STATES  
Fu, Xiaoli, Carlsbad, CA, UNITED STATES  
Nouraini, Sherry, Vista, CA, UNITED STATES  
Zhang, Zhiqing, Carlsbad, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005075298	A1	20050407
APPLICATION INFO.:	US 2003-353149	A1	20030127 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-280769, filed on 25 Oct 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-401465P	20020805 (60)
	US 2002-353885P	20020131 (60)
	US 2002-353923P	20020131 (60)
	US 2002-353964P	20020131 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ATTN: Louis C Cullman, Stradling Yocca Carlson & Rauth, Suite 1600, 660 Newport Center Drive, Newport Beach, CA, 92660	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	2955	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions are provided for in vivo heterologous nucleic acid delivery using genetically modified microflora. Specifically, compositions and related methods for the delivery of heterologous nucleic acids to the intestinal mucosa of animals are provided. Specifically, genetically modified microflora are used to deliver transforming heterologous nucleic acids directly, or genetically modified microflora **expressing** at least one heterologous nucleic acid are provided. Representative microflora include bacteria, bacterial fusions, and yeast. The heterologous nucleic acid may encode for immunoprotective epitopes (antigens) or other gene therapy applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2005:37507 USPATFULL  
TITLE: Regulatory zinc finger proteins  
INVENTOR(S): Kim, Jin-Soo, Daejeon, KOREA, REPUBLIC OF  
Shin, Hyun-Chul, Daejeon, KOREA, REPUBLIC OF  
Kwon, Heung-Sun, Daejeon, KOREA, REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005032186	A1	20050210
APPLICATION INFO.:	US 2003-732620	A1	20031209 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-431892P	20021209 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	36	

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 16 Drawing Page(s)  
LINE COUNT: 5012  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Disclosed are chimeric zinc finger proteins that can regulate endogenous genes. Examples of such proteins include proteins that can regulate VEGF-A **expression**. The proteins and nucleic acid encoding them can be used to modulate angiogenesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 44 USPATFULL on STN  
ACCESSION NUMBER: 2004:334808 USPATFULL  
TITLE: Novel human leucine-rich repeat containing protein **expressed** predominately in small intestine, HLRSI1  
INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES  
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES  
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004265890	A1	20041230
APPLICATION INFO.:	US 2004-882761	A1	20040701 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-29347, filed on 20 Dec 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-257774P	20001222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	14389	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRSI1 polypeptides, fragments and homologues thereof. Also provided are **vectors**, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 44 USPATFULL on STN  
ACCESSION NUMBER: 2004:299230 USPATFULL  
TITLE: Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof  
INVENTOR(S): Zhang, Jianzhong, North Wales, PA, UNITED STATES  
Cress, Dean Ervin, Souderton, PA, UNITED STATES  
Palli, Subba Reddy, Lansdale, PA, UNITED STATES  
Dhadialla, Tarlochart Singh, Chalfont, PA, UNITED STATES

NUMBER	KIND	DATE
-----		

PATENT INFORMATION:	US 2004235097	A1	20041125	
APPLICATION INFO.:	US 2004-490976	A1	20040325	(10)
	WO 2002-US5234		20020220	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-60325534	20010926
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Camille Jolly Tornetta, RheoGene, 2650 Eisenhower Avenue, Norristown, PA, 19403	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	3812	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to **vectors** comprising them and to their uses, in particular in methods for modulating gene **expression** in an ecdysone receptor-based gene **expression** modulation system and methods for identifying molecules that modulate whitefly ecdysone receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 44 USPATFULL on STN  
 ACCESSION NUMBER: 2004:294587 USPATFULL  
 TITLE: Compositions and methods for increasing packaging and yield of recombinant adenoviruses using multiple packaging signals  
 INVENTOR(S): Gao, Guangping, Rosemont, PA, United States  
 Wilson, James M., Gladwyne, PA, United States  
 PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6821512	B1	20041123
	WO 2001040455		20010607
APPLICATION INFO.:	US 2002-169544		20020530 (10)
	WO 2000-US32235		20001127

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169025P	19991203 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Guzo, David	
LEGAL REPRESENTATIVE:	Howson and Howson	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1059	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A recombinant adenoviral **vector** which has multiple adenovirus packaging domains is provided. This **vector** has advantages over conventional adenoviral **vectors** in packaging plasmid **vectors** into adenoviral capsids. Methods of making and using this **vector** are described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2004:273303 USPATFULL  
TITLE: Antibodies against PD-1 and uses therefor  
INVENTOR(S): Collins, Mary, Natick, MA, UNITED STATES  
Wood, Clive R., Boston, MA, UNITED STATES  
Carreno, Beatriz M., Acton, MA, UNITED STATES  
Luxenberg, Deborah, Melrose, MA, UNITED STATES  
Jussif, Jason, Salem, NH, UNITED STATES  
Carter, Laura L., Medford, MA, UNITED STATES  
Bennett, Frances K., Sudbury, MA, UNITED STATES  
Valge-Archer, Viia, Little Abington, UNITED KINGDOM  
Andrews, John, Little Hadham Ware, UNITED KINGDOM  
Russell, Caroline, Royston, UNITED KINGDOM  
PATENT ASSIGNEE(S): Wyeth, Madison, NJ, UNITED STATES (U.S. corporation)  
Cambridge Antibody Technology, Cambridge, UNITED  
KINGDOM (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004213795	A1	20041028
APPLICATION INFO.:	US 2003-741481	A1	20031222 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-435354P	20021223 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Mary K. Ferguson, FINNEGAN, HENDERSON, FARABOW,, GARRETT & DUNNER, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	2114	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2004:267736 USPATFULL  
TITLE: Differentiation proteins  
INVENTOR(S): Lee, Dong-Ki, Daejeon, KOREA, REPUBLIC OF  
Lee, Yangsoon, Daejeon, KOREA, REPUBLIC OF  
Kim, Jin-Soo, Daejeon, KOREA, REPUBLIC OF  
PATENT ASSIGNEE(S): TOOLGEN, INC (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004209277	A1	20041021
APPLICATION INFO.:	US 2003-669861	A1	20030924 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-314669, filed on 9 Dec 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-338441P	20011207 (60)
	US 2002-376053P	20020426 (60)

US 2002-400904P 20020802 (60)  
 US 2002-401089P 20020805 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110  
 NUMBER OF CLAIMS: 21  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 27 Drawing Page(s)  
 LINE COUNT: 8164

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The disclosure describes artificial chimeric transcription factors that include at least one zinc finger domains and that can regulate cellular differentiation, for example, a neuronal cell phenotype or an osteoblast phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2004:254335 USPATFULL  
 TITLE: Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof  
 INVENTOR(S): Palli, Subba Reddy, Lansdale, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004197861	A1	20041007
APPLICATION INFO.:	US 2004-490971	A1	20040325 (10)
	WO 2002-US5026		20020220

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-60325096	20010926
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Camille Jolly-Tornetta, RheoGene, 2650 Eisenhower Avenue, Norristown, PA, 19403	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	3776	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel isolated leafhopper ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the leafhopper ecdysone receptor polypeptide, to **vectors** comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene **expression** modulation system and methods for identifying molecules that modulate leafhopper ecdysone receptor activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2004:232975 USPATFULL  
 TITLE: Bispecific molecules and uses thereof  
 INVENTOR(S): Himawan, Jeff, Tampa, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004180046	A1	20040916
APPLICATION INFO.:	US 2004-258650	A1	20040303 (10)
	WO 2001-US13161		20010424

NUMBER	DATE
--------	------

-----  
PRIORITY INFORMATION: US 2000-199903P 20000426 (60)  
US 2000-244812P 20001101 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017  
NUMBER OF CLAIMS: 119  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 6 Drawing Page(s)  
LINE COUNT: 2677

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to bispecific molecules that are characterized by having a first binding domain which binds an antigen present in the circulation of a mammal and a second binding domain which binds the C3b-like receptor (known as complement receptor 1 (CR1) or CD35 in primates). The bispecific molecules do not consist of a first monoclonal antibody to CR1 that has been chemically cross-linked to a second monoclonal antibody. The invention also relates to methods of making the bispecific molecules and therapeutic uses thereof, as well as to kits containing the bispecific molecules. The invention further provides polyclonal populations of bispecific molecules, which comprise populations of bispecific molecules with different antigen recognition specificities. Such polyclonal populations of bispecific molecules can be used for targeting multiple epitopes of a pathogenic antigenic molecule and/or multiple variants of a pathogenic antigenic molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2004:221879 USPATFULL

TITLE: Oxadiazoline ligands for modulating the  
expression of exogenous genes via an ecdysone  
receptor complex

INVENTOR(S): Hormann, Robert Eugene, Melrose Park, PA, UNITED STATES  
Chortyk, Orestes, Thompson Station, TN, UNITED STATES  
Le, Dat Phat, North Wales, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004171651	A1	20040902
APPLICATION INFO.:	US 2004-783810	A1	20040219 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-449467P	20030221 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Rheo Gene INC., 2650 Eisenhower Avenue, Norristown, PA, 19403	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6195	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene **expression** system, and a method to modulate exogenous gene **expression** in which an ecdysone receptor complex comprising: a DNA binding **domain**; a ligand binding **domain**; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2004:158597 USPATFULL

TITLE: Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses

INVENTOR(S): Fraser, Christopher C., Lexington, MA, UNITED STATES  
Barnes, Thomas M., Brookline, MA, UNITED STATES  
Sharp, John D., Arlington, MA, UNITED STATES  
Kirst, Susan J., Brookline, MA, UNITED STATES  
Myers, Paul S., Cambridge, MA, UNITED STATES  
Leiby, Kevin R., Natick, MA, UNITED STATES  
Holtzman, Douglas A., Jamaica Plain, MA, UNITED STATES  
McCarthy, Sean A., San Diego, CA, UNITED STATES  
Wrighton, Nicholas, Winchester, MA, UNITED STATES  
MacKay, Charles R., Vaucluse, AUSTRALIA  
Goodearl, Andrew D.J., Natick, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004121396	A1	20040624
APPLICATION INFO.:	US 2003-741790	A1	20031219 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-759130, filed on 12 Jan 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-479249, filed on 7 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-559497, filed on 27 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-578063, filed on 24 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-333159, filed on 14 Jun 1999, PENDING Continuation-in-part of Ser. No. US 2000-596194, filed on 16 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-342364, filed on 29 Jun 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-608452, filed on 30 Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-393996, filed on 10 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-602871, filed on 23 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-420707, filed on 19 Oct 1999, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139		
NUMBER OF CLAIMS:	85		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	365 Drawing Page(s)		
LINE COUNT:	12420		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, **expression vectors** containing the nucleic acid molecules of the invention, host cells into which the **expression vectors** have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2004:133830 USPATFULL

TITLE: Gene **expression** system based on chimeric receptors

INVENTOR(S): Gage, Fred H, La Jolla, CA, UNITED STATES  
Suhr, Steven T, La Jolla, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004102367	A1	20040527
APPLICATION INFO.:	US 2002-181325	A1	20021122 (10)
	WO 2001-US5750		20010223
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278		
NUMBER OF CLAIMS:	46		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		
LINE COUNT:	1953		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a system for modulating the **expression** of a target gene in a subject wherein a defined response element for a DNA binding domain modulates **expression** of said target gene. The invention system comprises two chimeric proteins, each containing the dimerization domain of a member of the steroid/thyroid hormone nuclear receptor superfamily, one of which is non-endogenous to the subject. In addition, the first chimeric protein contains a DNA binding domain to which the target gene is responsive and the second chimeric protein contains a transcription modulating domain, such as a transcription activator or a transcription repressor. In one embodiment of the invention, two invention systems form a dimer having the properties of a native heterodimer or homodimer. In another embodiment, only the first chimeric protein contains a DNA binding domain and only the second chimeric protein contains a transcription activating domain. The functional entity formed by association of the first and second chimeric proteins can be designed to transactivate transcription by complexing with a DNA binding recognition site that does not have the 2-half site format common to response elements for members of the steroid/thyroid hormone nuclear receptor superfamily. Thus, certain of the invention systems cannot functionally interact with endogenous proteins in the way that wild type receptors do. The invention further provides nucleic acid sequences encoding the invention chimeric proteins, cells containing such nucleic acid sequences, and methods for using the invention chimeric proteins to modulate **expression** of one or more non-endogenous genes in a subject organism.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2004:126963 USPATFULL

TITLE: Chimeric retinoid X receptors and their use in a novel ecdysone receptor-based inducible gene **expression** system

INVENTOR(S): Kapitskaya, Marianna Zinovjevna, North Wales, PA, UNITED STATES  
Palli, Subba Reddy, Lansdale, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004096942	A1	20040520



APPLICATION INFO.: US 2003-468199 A1 20031217 (10)  
WO 2002-US5706 20020220  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Rachel Rondinelli, Rohm & Haas Company, 100  
Independence Mall West, Philadelphia, PA, 19106-2399  
NUMBER OF CLAIMS: 65  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 9 Drawing Page(s)  
LINE COUNT: 5388

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene **expression**. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene **expression** system and methods of modulating gene **expression** in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation traits in transgenic organisms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2004:64518 USPATFULL  
TITLE: Ketone ligands for modulating the **expression**  
of exogenous genes via an ecdysone receptor complex  
INVENTOR(S): Tice, Colin M., Elkins Park, PA, UNITED STATES  
Michelotti, Enrique L., Fort Washington, PA, UNITED STATES  
Hormann, Robert E., Melrose Park, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049037	A1	20040311
APPLICATION INFO.:	US 2003-614116	A1	20030703 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-393960P	20020705 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	RheoGene, Inc., 2650 Eisenhower Avenue, Norristown, PA, 19403	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	8313	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a method to modulate exogenous gene **expression** in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain ; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. The ligands comprise a class of ketones.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 44 USPATFULL on STN

ACCESSION NUMBER: ~~2004~~:44607 USPATFULL  
TITLE: Ecdysone receptor-based inducible gene

INVENTOR(S) : **expression system**  
Palli, Subba Reddy, Lansdale, PA, UNITED STATES  
Kapitskaya, Marianna Zinovjevna, North Wales, PA,  
UNITED STATES  
Cress, Dean Ervin, Sounderton, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004033600	A1	20040219
APPLICATION INFO.:	US 2002-239134	A1	20020919 (10)
	WO 2001-US9050		20010321
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NEW RHEOGENE I LLC, 2650 EISENHOWER AVENUE, NORRISTOWN, PA, 19403		
NUMBER OF CLAIMS:	71		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	5380		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene **expression** More specifically, this invention relates to a novel inducible gene **expression** system and methods of modulating gene **expression** in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 44 USPATFULL on STN  
ACCESSION NUMBER: 2004:24751 USPATFULL  
TITLE: Combinatorial DNA library for producing modified N-glycans in lower eukaryotes

INVENTOR(S) :  
Gerngross, Tillman U., Hanover, NH, UNITED STATES  
Wildt, Stefan, Lebanon, NH, UNITED STATES  
Choi, Byung-Kwon, Norwich, VT, UNITED STATES  
Nett, Juergen Hermann, Grantham, NH, UNITED STATES  
Bobrowicz, Piotr, White River Junction, VT, UNITED STATES  
Hamilton, Stephen R., Enfield, NH, UNITED STATES  
Davidson, Robert C., Enfield, NH, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004018590	A1	20040129
APPLICATION INFO.:	US 2003-371877	A1	20030220 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-892591, filed on 27 Jun 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-214358P	20000628 (60)
	US 2000-215638P	20000630 (60)
	US 2001-279997P	20010330 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105	
NUMBER OF CLAIMS:	76	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	45 Drawing Page(s)	
LINE COUNT:	5213	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous **expression** of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The invention provides nucleic acid molecules and combinatorial libraries which can be used to successfully target and **express** mammalian enzymatic activities such as those involved in glycosylation to intracellular compartments in a eukaryotic host cell. The process provides an engineered host cell which can be used to **express** and target any desirable gene(s) involved in glycosylation. Host cells with modified oligosaccharides are created or selected. N-glycans made in the engineered host cells have a Man.sub.5GlcNAc.sub.2 core structure which may then be modified further by heterologous **expression** of one or more enzymes, e.g., glycosyltransferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2004:13415 USPATFULL

TITLE: ~~Method~~ Methods and composition for delivering nucleic acids and/or proteins to the respiratory system

INVENTOR(S): Chen, Wei, San Diego, CA, UNITED STATES  
Fu, Xiaoli, Carlsbad, CA, UNITED STATES  
Nouraini, Sherry, Vista, CA, UNITED STATES  
Zhang, Zhiqing, Carlsbad, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009937	A1	20040115
APPLICATION INFO.:	US 2003-353137	A1	20030127 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-280769, filed on 25 Oct 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-401465P	20020805 (60)
	US 2002-353885P	20020131 (60)
	US 2002-353923P	20020131 (60)
	US 2002-353964P	20020131 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: OPPENHEIMER WOLFF & DONNELLY LLP, 840 NEWPORT CENTER DRIVE, SUITE 700, NEWPORT BEACH, CA, 92660

NUMBER OF CLAIMS: 33

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Page(s)

LINE COUNT: 2577

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions related to the fields of bacteriology, immunology and gene therapy are provided. In general modified microflora for the delivery of vaccines, allergens and therapeutics to the mucosal surfaces of the respiratory tract are provided. In particular, the compositions and methods are directed at inducing an M-cell mediated immune response to pathogenic diseases. Specifically, methods of vaccine preparation, delivery and mucosal immunization using a Lactic Acid Bacteria (LAB), yeast and LAB that have been modified through fusion with E. coli to either present on its cell surface, or secrete, antigenic epitopes derived from pathogenic microorganisms and/or to secrete a therapeutic protein sequence are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2003:335013 USPATFULL

TITLE: Materials and methods involving conditional retention domains

INVENTOR(S): Rivera, Victor, Arlington, MA, UNITED STATES  
Clackson, Timothy P., Arlington, MA, UNITED STATES  
Rothman, James E., New York, NY, UNITED STATES

PATENT ASSIGNEE(S): ARIAD Gene Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003235889	A1	20031225
APPLICATION INFO.:	US 2003-440799	A1	20030519 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-420819, filed on 19 Oct 1999, GRANTED, Pat. No. US 6566073 Continuation of Ser. No. US 1998-174799, filed on 19 Oct 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-104743P	19981019 (60)
	US 1999-137787P	19990602 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ARIAD Gene Therapeutics, Inc., 26 Landsdowne Street, Cambridge, MA, 02139-4234	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	3859	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Materials and methods involving conditional retention domains (CRDs) are disclosed. Also disclosed are fusion proteins containing CRDs and cells **expressing** such fusion proteins. In addition, the invention provides novel methods for producing target proteins in vivo using fusion proteins containing conditional retention domains and methods for identifying novel CRDs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2003:276702 USPATFULL

TITLE: Phenotypic screen of chimeric proteins

INVENTOR(S): Kim, Jin-Soo, Yuseong-gu, KOREA, REPUBLIC OF  
Park, Kyung-Soon, Yuseong-gu, KOREA, REPUBLIC OF  
Lee, Dong-Ki, Yuseong-gu, KOREA, REPUBLIC OF  
Seol, Wongi, Yuseong-gu, KOREA, REPUBLIC OF  
Lee, Horim, Chungcheongnam-do, KOREA, REPUBLIC OF  
Lee, Seong-Il, Yuseong-gu, KOREA, REPUBLIC OF  
Yang, Hyo-Young, Yuseong-gu, KOREA, REPUBLIC OF  
Lee, Yangsoon, Yuseong-gu, KOREA, REPUBLIC OF  
Jang, Young-Soon, Yuseong-gu, KOREA, REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003194727	A1	20031016
APPLICATION INFO.:	US 2002-314669	A1	20021209 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-338441P	20011207 (60)

US 2002-376053P 20020426 (60)  
 US 2002-400904P 20020802 (60)  
 US 2002-401089P 20020805 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA,  
 02110  
 NUMBER OF CLAIMS: 111  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 28 Drawing Page(s)  
 LINE COUNT: 5577

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In one aspect, a library of nucleic acids that encode different artificial, chimeric proteins is screened to identify a chimeric protein that alters a phenotypic trait of a cell or organism. The chimeric protein can be identified without a priori knowledge of a particular target gene or pathway. Some chimeric proteins include multiple zinc finger domains and can induce, for example, thermotolerance, solvent-tolerance, altered cellular growth, insulin production, differentiation, and drug resistance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 44 USPATFULL on STN  
 ACCESSION NUMBER: ~~2003~~:238378 USPATFULL  
 TITLE: Modified **factor VIII**  
 INVENTOR(S): Lollar, John S., Decatur, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166536	A1	20030904
APPLICATION INFO.:	US 2002-131510	A1	20020423 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-315179, filed on 20 May 1999, GRANTED, Pat. No. US 6376463 Continuation-in-part of Ser. No. US 1998-37601, filed on 10 Mar 1998, GRANTED, Pat. No. US 6180371 Continuation-in-part of Ser. No. US 1996-670707, filed on 26 Jun 1996, GRANTED, Pat. No. US 5859204 Continuation-in-part of Ser. No. WO 1994-US13200, filed on 15 Nov 1994, PENDING Continuation-in-part of Ser. No. US 1994-212133, filed on 11 Mar 1994, GRANTED, Pat. No. US 5663060 Continuation-in-part of Ser. No. US 1992-864004, filed on 7 Apr 1992, GRANTED, Pat. No. US 5364771 Continuation-in-part of Ser. No. WO 1997-US11155, filed on 26 Jun 1997, PENDING		

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: GREENLEE WINNER AND SULLIVAN P C, 5370 MANHATTAN  
 CIRCLE, SUITE 201, BOULDER, CO, 80303  
 NUMBER OF CLAIMS: 25  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 6 Drawing Page(s)  
 LINE COUNT: 5600

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Specific amino acid loci of human **factor VIII** interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with **factor VIII**. Modified **factor VIII** is disclosed in which the amino acid sequence is changed by a substitution at one or more amino acids of positions 484-508 of the A2 domain. The modified **factor VIII** is useful as a clotting factor supplement for hemophiliacs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 27 OF 44 USPATFULL on STN  
ACCESSION NUMBER: 2003:225297 USPATFULL  
TITLE: Glycoprotein compositions  
INVENTOR(S): Presta, Leonard G., San Francisco, CA, UNITED STATES  
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003157108	A1	20030821
APPLICATION INFO.:	US 2002-277370	A1	20021022 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-337642P	20011025 (60)
	US 2002-347694P	20020109 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	4803	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 28 OF 44 USPATFULL on STN  
ACCESSION NUMBER: 2003:207348 USPATFULL  
TITLE: Novel human leucine-rich repeat containing protein  
**expressed** predominately in bone marrow, HLRRBM1  
INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES  
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES  
Mintier, Gabe, Hightstown, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003143706	A1	20030731
APPLICATION INFO.:	US 2001-28374	A1	20011220 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-257773P	20001222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	13850	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRRBM1 polypeptides, fragments and homologues thereof. Also provided are **vectors**, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRBM1 polypeptides to the diagnosis, treatment, and/or prevention of various

diseases and/or disorders related to these polypeptides, particularly immune diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 29 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2003:194977 USPATFULL

TITLE: Human tumor necrosis factor receptor TR16

INVENTOR(S): Baker, Kevin P., Darnestown, MD, UNITED STATES

Young, Paul E., Gaithersburg, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003134788	A1	20030717
APPLICATION INFO.:	US 2002-73333	A1	20020213 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-637856, filed on 10 Aug 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-268364P	20010214 (60)
	US 1999-148348P	19990812 (60)
	US 1999-148683P	19990813 (60)
	US 1999-148758P	19990816 (60)
	US 1999-148870P	19990813 (60)
	US 1999-149181P	19990817 (60)
	US 1999-149453P	19990818 (60)
	US 1999-149498P	19990819 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 20 Drawing Page(s)

LINE COUNT: 13800

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel protein, TR16, which is a member of the tumor necrosis factor (TNF) receptor superfamily and the TRAIL receptor subfamily. In particular, isolated nucleic acid molecules are provided encoding the human TR16 protein. TR16 polypeptides are also provided as are **vectors**, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR16 activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 30 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2003:175214 USPATFULL

TITLE: Compositions and methods of use of mammalian retrotransposons

INVENTOR(S): Kazazian, Haig H., JR., Baltimore, MD, UNITED STATES

Ostertag, Eric, Philadelphia, PA, UNITED STATES

DeBerardinis, Ralph, Philadelphia, PA, UNITED STATES

PATENT ASSIGNEE(S): The Trustees Of The University Of Pennsylvania (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003121063	A1	20030626
APPLICATION INFO.:	US 2002-216122	A1	20020809 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-653812, filed on 1 Sep 2000, PENDING Division of Ser. No. US 1997-847844, filed on 28 Apr 1997, GRANTED, Pat. No. US 6150160 Continuation-in-part of Ser. No. US 1996-749805, filed on 15 Nov 1996, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-6831P	19951116 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	44 Drawing Page(s)	
LINE COUNT:	4178	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to an isolated DNAC molecule comprising a promoter P and an L1 cassette sequence comprising a core L1 retrotransposon element and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 31 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2003:136920 USPATFULL

TITLE: Materials and methods involving conditional retention domains

INVENTOR(S): Rivera, Victor, Arlington, MA, United States  
Clackson, Timothy, Cambridge, MA, United States  
Rothman, James, New York, NY, United States

PATENT ASSIGNEE(S): Ariad Gene Therapeutics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6566073	B1	20030520
APPLICATION INFO.:	US 1999-420819		19991019 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-174799, filed on 19 Oct 1998, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-137787P	19990602 (60)
	US 1998-104743P	19981019 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Horlick, Kenneth R.	
ASSISTANT EXAMINER:	Wilder, Cynthia	
LEGAL REPRESENTATIVE:	Berstein, David L.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	3873	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Materials and methods involving conditional retention domains (CRDs) are disclosed. Also disclosed are fusion proteins containing CRDs and cells **expressing** such fusion proteins. In addition, the invention provides novel methods for producing target proteins in vivo using fusion proteins containing conditional retention domains and methods for identifying novel CRDs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



L5 ANSWER 32 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2003:106253 USPATFULL  
TITLE: Prokaryotically produced antibodies and uses thereof  
INVENTOR(S): Simmons, Laura C., Burlingame, CA, UNITED STATES  
Klimowski, Laura, Salt Lake City, UT, UNITED STATES  
Reilly, Dorothea, San Francisco, CA, UNITED STATES  
Yansura, Daniel G., Pacifica, CA, UNITED STATES  
PATENT ASSIGNEE(S): GENENTECH, INC. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073164	A1	20030417
APPLICATION INFO.:	US 2001-20786	A1	20011213 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256164P	20001214 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	

NUMBER OF CLAIMS: 41  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 26 Drawing Page(s)  
LINE COUNT: 3112

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods and compositions for improved **expression** and production of recombinant antibodies in prokaryotic **expression** systems. Particularly contemplated are prokaryotic **expression** and production of full length aglycosylated antibodies. The antibody products of the invention can be used in various aspects of biological research, diagnosis and medical treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 33 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2003:30332 USPATFULL  
TITLE: Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses  
INVENTOR(S): Fraser, Christopher C., Lexington, MA, UNITED STATES  
Barnes, Thomas M., Brookline, MA, UNITED STATES  
Sharp, John D., Arlington, MA, UNITED STATES  
Kirst, Susan J., Brookline, MA, UNITED STATES  
Myers, Paul S., Cambridge, MA, UNITED STATES  
Leiby, Kevin R., Natick, MA, UNITED STATES  
Holtzman, Douglas A., Jamaica Plain, MA, UNITED STATES  
McCarthy, Sean A., San Diego, CA, UNITED STATES  
Wrighton, Nicholas, Winchester, MA, UNITED STATES  
MacKay, Charles R., Vaucluse, AUSTRALIA  
Goodearl, Andrew D.J., Natick, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022279	A1	20030130
APPLICATION INFO.:	US 2001-759130	A1	20010112 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-479249, filed on 7 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-559497, filed on 27 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-578063, filed on 24 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-333159, filed on 14 Jun 1999, PENDING Continuation-in-part of Ser. No. US 2000-596194, filed on 16 Jun 2000, PENDING Continuation-in-part of Ser.		

No. US 1999-342364, filed on 29 Jun 1999, ABANDONED  
Continuation-in-part of Ser. No. US 2000-608452, filed  
on 30 Jun 2000, PENDING Continuation-in-part of Ser.  
No. US 1999-393996, filed on 10 Sep 1999, ABANDONED  
Continuation-in-part of Ser. No. US 2000-602871, filed  
on 23 Jun 2000, ABANDONED Continuation-in-part of Ser.  
No. US 1999-420707, filed on 19 Oct 1999, ABANDONED

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Jean M. Silveri, Millenium Pharmaceuticals, Inc., 75  
Sidney Street, Cambridge, MA, 02139  
NUMBER OF CLAIMS: 85  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 361 Drawing Page(s)  
LINE COUNT: 12618

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids encoding a variety of  
proteins having diagnostic, preventive, therapeutic, and other uses.  
These nucleic and proteins are useful for diagnosis, prevention, and  
therapy of a number of human and other animal disorders. The invention  
also provides antisense nucleic acid molecules, **expression  
vectors** containing the nucleic acid molecules of the invention,  
host cells into which the **expression vectors** have  
been introduced, and non-human transgenic animals in which a nucleic  
acid molecule of the invention has been introduced or disrupted. The  
invention still further provides isolated polypeptides, fusion  
polypeptides, antigenic peptides and antibodies. Diagnostic, screening,  
and therapeutic methods using compositions of the invention are also  
provided. The nucleic acids and polypeptides of the present invention  
are useful as modulating agents in regulating a variety of cellular  
processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 34 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2003;23722 USPATFULL  
TITLE: Novel human leucine-rich repeat containing protein  
**expressed** predominately in small intestine,  
HLRRSI1

INVENTOR(S): Feder, John N., Belle Mead, NJ, UNITED STATES  
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES  
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003017562	A1	20030123
	US 6858407	B2	20050222
APPLICATION INFO.:	US 2001-29347	A1	20011220 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-257774P	20001222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	14217	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRRSI1  
polypeptides, fragments and homologues thereof. Also provided are  
**vectors**, host cells, antibodies, and recombinant and synthetic

methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 35 OF 44 USPATFULL on STN  
ACCESSION NUMBER: 2002:322506 USPATFULL  
TITLE: Modified factor VIII  
INVENTOR(S): Lollar, John S., Decatur, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002182670	A1	20021205
	US 6770744	B2	20040803
APPLICATION INFO.:	US 2001-957641	A1	20010919 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-236460P	20000929 (60)
	US 2000-234047P	20000919 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GREENLEE WINNER and SULLIVAN, P.C., Suite 201, 5370 Manhattan Circle, Boulder, CO, 80303	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2392	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Specific amino acid loci of human **factor VIII** interact with inhibitory antibodies of hemophilia patients after being treated with **factor VIII**. Modified **factor VIII** is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified **factor VIII** is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 36 OF 44 USPATFULL on STN  
ACCESSION NUMBER: 2002:254199 USPATFULL  
TITLE: Modified factor VIII  
INVENTOR(S): Lollar, John S., Decatur, GA, United States  
PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6458563	B1	20021001
APPLICATION INFO.:	US 2000-523656		20000310 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-37601, filed on 10 Mar 1998, now patented, Pat. No. US 6180371		
	Continuation-in-part of Ser. No. US 1996-670707, filed on 26 Jun 1996, now patented, Pat. No. US 5859204		
	Continuation-in-part of Ser. No. US 523656		
	Continuation-in-part of Ser. No. WO 1997-US11155, filed on 26 Jun 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		

PRIMARY EXAMINER: Low, Christopher S. F.  
ASSISTANT EXAMINER: Schnizer, Holly  
LEGAL REPRESENTATIVE: Greenlee Winner and Sullivan PC  
NUMBER OF CLAIMS: 10  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 6 Drawing Page(s)  
LINE COUNT: 4222

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a modified B-domainless form of porcine **factor VIII**, to a DNA encoding the same, and to the use thereof for treatment of hemophilia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 37 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2002:221381 USPATFULL

TITLE: Novel ecdysone receptor-based inducible gene **expression** system

INVENTOR(S): Palli, Subba Reddy, Lansdale, PA, UNITED STATES  
Kapitskaya, Marianna Zinovjevna, North Wales, PA, UNITED STATES  
Cress, Dean Ervin, Souderton, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002119521	A1	20020829
APPLICATION INFO.:	US 2001-965703	A1	20010926 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-US9050, filed on 21 Mar 2001, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-191355P	20000322 (60)
	US 2001-269799P	20010220 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROHM AND HAAS COMPANY, PATENT DEPARTMENT, 100 INDEPENDENCE MALL WEST, PHILADELPHIA, PA, 19106-2399	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	6231	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene **expression**. More specifically, this invention relates to a novel inducible gene **expression** system and methods of modulating gene **expression** in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic plants and animals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 38 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2002:206168 USPATFULL

TITLE: Multiple inducible gene regulation system

INVENTOR(S): Dhadialla, Tarlochan Singh, Indianapolis, IN, UNITED STATES  
Cress, Dean Ervin, Souderton, PA, UNITED STATES  
Carlson, Glenn Richard, North Wales, PA, UNITED STATES  
Hormann, Robert Eugene, Melrose Park, PA, UNITED STATES  
Palli, Subba Reddy, Lansdale, PA, UNITED STATES  
Kudla, Arthur John, Charlottesville, VA, UNITED STATES

Herzig, Ronald Phillip, JR., Barboursville, VA, UNITED STATES

Philip, Mohan, Charlottesville, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002110861	A1	20020815
APPLICATION INFO.:	US 2001-965697	A1	20010927 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-237446P	20001003 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz, Mackiewicz & Norris LLP, One Liberty Place - 46th Floor, Philadelphia, PA, 19103	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	3413	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative **expression** of multiple genes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 39 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2002:185256 USPATFULL  
TITLE: Human tumor necrosis factor receptors TR21 and TR22  
INVENTOR(S): Zeng, Zhi-Zhen, Lansdale, PA, UNITED STATES  
Ruben, Steven M., Olney, MD, UNITED STATES  
Rosen, Craig A., Laytonsville, MD, UNITED STATES  
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098163	A1	20020725
APPLICATION INFO.:	US 2001-910562	A1	20010723 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US23124	20010723
	US 2000-220116P	20000724 (60)
	US 2000-221143P	20000727 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 21  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 12 Drawing Page(s)  
LINE COUNT: 9204

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to two novel proteins, TR21 and TR22, which are members of the tumor necrosis factor (TNF) receptor. In particular, isolated nucleic acid molecules are provided encoding the human TR21 and TR22 protein. TR21 and TR22 polypeptides are also provided as are **vectors**, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 and TR22

activity; and methods of treating immune disorders by administering TR21 and TR22 polynucleotides, polypeptides, agonists, and antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 40 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2002:88455 USPATFULL  
TITLE: Modified factor VIII  
INVENTOR(S): Lollar, John S., Decatur, GA, United States  
PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6376463	B1	20020423
APPLICATION INFO.:	US 1999-315179		19990520 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-670707, filed on 26 Jun 1996, now patented, Pat. No. US 5859204 Continuation-in-part of Ser. No. WO 1994-US13200, filed on 15 Nov 1994 Continuation-in-part of Ser. No. US 1994-212133, filed on 11 Mar 1994 Continuation-in-part of Ser. No. US 1992-864004, filed on 7 Apr 1992, now patented, Pat. No. US 5364771		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Carlson, Karen Cochrane		
ASSISTANT EXAMINER:	Robinson, Hope A.		
LEGAL REPRESENTATIVE:	Greenlee Winner and Sullivan, PC		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	5454		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Specific amino acid loci of human **factor VIII** interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with **factor VIII**. Modified **factor VIII** is disclosed in which the amino acid sequence is changed by a substitution at one or more amino acids of positions 484-508 of the Az domain. The modified **factor VIII** is useful as a clotting factor supplement for hemophiliacs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 41 OF 44 USPATFULL on STN

ACCESSION NUMBER: 2002:8587 USPATFULL  
TITLE: Multivalent antibodies and uses therefor  
INVENTOR(S): Miller, Kathy L., San Francisco, CA, UNITED STATES  
Presta, Leonard G., San Francisco, CA, UNITED STATES  
PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004587	A1	20020110
APPLICATION INFO.:	US 2001-813341	A1	20010320 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-195819P	20000411 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Attn: Wendy M. Lee, 1 DNA Way, South San Francisco, CA, 94080-4990	
NUMBER OF CLAIMS:	93	

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 45 Drawing Page(s)  
LINE COUNT: 4913  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 42 OF 44 USPATFULL on STN  
ACCESSION NUMBER: 92:38505 USPATFULL  
TITLE: **Factor VIII** analog, preparation  
process, and pharmaceutical composition containing it  
INVENTOR(S): Meulien, Pierre, Strasbourg, France  
Pavirani, Andrea, Strasbourg, France  
PATENT ASSIGNEE(S): Transgene S.A., Courbevoie, France (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5112950		19920512
APPLICATION INFO.:	US 1991-723666		19910626 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1988-228265, filed on 4 Aug 1988, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1987-11415	19870811
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wax, Robert A.	
ASSISTANT EXAMINER:	Baker, R. Keith	
LEGAL REPRESENTATIVE:	Cushman, Darby & Cushman	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	401	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Factor VIII** analog which has undergone deletion of amino acids 771 to 1666, prepared from eukaryotic cells transformed by an **expression vector** carrying the cDNA of the **factor VIII** which has undergone deletion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 43 OF 44 USPAT2 on STN  
ACCESSION NUMBER: 2003:23722 USPAT2  
TITLE: **Human** leucine-rich repeat containing protein **expressed** predominately in small intestine, HLRRSI1  
INVENTOR(S): Feder, John N., Belle Mead, NJ, United States  
Ramanathan, Chandra S., Wallingford, CT, United States  
Mintier, Gabriel A., Hightstown, NJ, United States  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6858407	B2	20050222
APPLICATION INFO.:	US 2001-29347		20011220 (10)

NUMBER	DATE
-----	

PRIORITY INFORMATION: US 2000-257774P 20001222 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: GRANTED  
PRIMARY EXAMINER: Nashed, Nashaat T.  
LEGAL REPRESENTATIVE: D'Amico, Stephen C.  
NUMBER OF CLAIMS: 13  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 16 Drawing Page(s)  
LINE COUNT: 14213

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding HLRRSI1 polypeptides, fragments and homologues thereof. Also provided are **vectors**, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRSI1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly gastrointestinal diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 44 OF 44 USPAT2 on STN  
ACCESSION NUMBER: 2002:322506 USPAT2  
TITLE: Modified **factor VIII**  
INVENTOR(S): Lollar, John S., Decatur, GA, United States  
PATENT ASSIGNEE(S): Emory University, Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6770744	B2	20040803
APPLICATION INFO.:	US 2001-957641		20010919 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-236460P	20000929 (60)
	US 2000-234047P	20000919 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Wax, Robert A.	
ASSISTANT EXAMINER:	Schnizer, Holly	
LEGAL REPRESENTATIVE:	Greenlee Winner and Sullivan PC	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	2460	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Specific amino acid loci of human **factor VIII** interact with inhibitory antibodies of hemophilia patients after being treated with **factor VIII**. Modified **factor VIII** is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified **factor VIII** is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



61 FILES SEARCHED...  
L6 52 NORDFANG

=> d L6 1-52 ibib,abs

L6 ANSWER 1 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2005:40112 USPATFULL  
TITLE: Peptides modulating activities of heparin other  
glycosaminoglycans or proteoglycans  
INVENTOR(S): San Antonio, James D., Media, PA, United States  
Verrecchio, Angela, Brighton, MA, United States  
Schick, Barbara P., Merion Station, PA, United States  
PATENT ASSIGNEE(S): Thomas Jefferson University, Philadelphia, PA, United  
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6855801	B1	20050215
APPLICATION INFO.:	US 2000-496391		20000202 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-118276P	19990202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Canella, Karen A.	
LEGAL REPRESENTATIVE:	Drinker Biddle & Reath LLP	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Figure(s); 11 Drawing Page(s)	
LINE COUNT:	2040	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves peptides of various sequences and sizes and methods of using said peptides with a strong affinity for glycosaminoglycans and proteoglycans, wherein said peptides interact strongly with heparin, other glycosaminoglycans, or proteoglycans (PGs).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:280870 USPATFULL  
TITLE: 1-Aroyl-piperidinyl benzamidines  
INVENTOR(S): Pauls, Heinz, Flemington, NJ, UNITED STATES  
Gong, Yong, Bridgewater, NJ, UNITED STATES  
Levell, Julian, Summit, NJ, UNITED STATES  
Astles, Peter, Kent, UNITED KINGDOM  
Eastwood, Paul R., Essex, UNITED KINGDOM  
PATENT ASSIGNEE(S): AVENTIS PHARMACEUTICALS INC, Bridgewater, NJ (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004220171	A1	20041104
APPLICATION INFO.:	US 2003-616141	A1	20030708 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-841417, filed on 24 Apr 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-18306	20000727
	US 2000-200066P	20000427 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE	

202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807  
NUMBER OF CLAIMS: 35  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3209  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB This invention relates to compounds of formula ##STR1##

which inhibit Factor Xa or tryptase, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa or tryptase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:267309 USPATFULL  
TITLE: Mini-Ad vector for immunization  
INVENTOR(S): Zhang, Wei-Wei, Libertyville, IL, UNITED STATES  
Alemany, Ramon, Grayslake, IL, UNITED STATES  
Dai, Yifan, Grayslake, IL, UNITED STATES  
Josephs, Steven, Grayslake, IL, UNITED STATES  
Balague, Cristina, Grayslake, IL, UNITED STATES  
Ayares, David, Blacksburgh, VA, UNITED STATES  
Schneiderman, Richard, Highland Park, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004208846	A1	20041021
APPLICATION INFO.:	US 2004-837079	A1	20040615 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-658961, filed on 31 May 1996, ABANDONED Continuation-in-part of Ser. No. US 1997-791218, filed on 31 Jan 1997, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-197734P	20000418 (60)
	US 2000-198501P	20000418 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MCDONNELL BOEHNNEN HULBERT & BERGHOFF LLP, 300 S. WACKER DRIVE, 32ND FLOOR, CHICAGO, IL, 60606	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	57 Drawing Page(s)	
LINE COUNT:	4461	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for treating a disorder such as hemophilia. A method of treating hemophilia in a mammal by administering recombinant virus virions comprising a nucleotide sequence having an adenoviral inverted terminal repeat fusion sequence, a packaging signal, a transcriptional control region, and a nucleic acid encoding a therapeutic protein such as FVIII. In addition, the DNA molecule does not encode an adenoviral protein. It is preferred that the virions be administered to the mammal under conditions that result in the expression of the therapeutic protein at a level that provides a therapeutic effect in said mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:178412 USPATFULL  
TITLE: Protein complexes having factor VIII:C activity and production thereof  
INVENTOR(S): Chapman, Barbara, Berkeley, CA, UNITED STATES

PATENT ASSIGNEE(S):  
Burke, Rae Lyn, San Francisco, CA, UNITED STATES  
Rasmussen, Mirella Ezban, Copenhagen, DENMARK  
Mikkelsen, Jan Mollar, Gentofte, DENMARK  
Chiron Corporation (U.S. corporation)  
Novo Nordisk A/S (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004137579	A1	20040715
APPLICATION INFO.:	US 2003-726199	A1	20031201 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-256849, filed on 26 Sep 2002, ABANDONED Continuation of Ser. No. US 2000-748062, filed on 22 Dec 2000, ABANDONED Continuation of Ser. No. US 1995-441943, filed on 16 May 1995, GRANTED, Pat. No. US 6228620 Division of Ser. No. US 1993-161770, filed on 3 Dec 1993, GRANTED, Pat. No. US 5595886 Continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, ABANDONED Continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, ABANDONED Continuation-in-part of Ser. No. US 1986-822989, filed on 27 Jan 1986, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Joseph H. Guth, Esq., CHIRON CORPORATION, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1986		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an  $\alpha$ .sub.1-antitrypsin signal sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:133913 USPATFULL  
TITLE: Substituted oxoazaheterocyclyl compounds  
INVENTOR(S): Ewing, William R., Yardley, PA, UNITED STATES  
Becker, Michael R., Norristown, PA, UNITED STATES  
Choi-Sledeski, Yong Mi, Belle Mead, NJ, UNITED STATES  
Pauls, Heinz W., Oakville, CANADA  
He, Wei, Audobon, PA, UNITED STATES  
Condon, Stephen M., Newton, MA, UNITED STATES  
Davis, Roderick S., West Chester, PA, UNITED STATES  
Hanney, Barbara A., Pennsburg, PA, UNITED STATES  
Spada, Alfred P., Carlsbad, CA, UNITED STATES  
Burns, Christopher J., Malvern, PA, UNITED STATES  
Jiang, John Z., Collegeville, PA, UNITED STATES  
Li, Aiwen, Audubon, PA, UNITED STATES  
Myers, Michael R., Fishers, IN, UNITED STATES  
Lau, Wan F., Groton, CT, UNITED STATES  
Poli, Gregory B., Perkasi, PA, UNITED STATES  
Bobko, Mark A., Exton, PA, UNITED STATES  
Morris, Robert L., Wayne, PA, UNITED STATES

Karpinski, Joseph M., Douglassville, PA, UNITED STATES  
Gallagher, Timothy F., Harleysville, PA, UNITED STATES  
Neuenschwander, Kent W., Schwenksville, PA, UNITED STATES  
Groneberg, Robert D., Boulder, CO, UNITED STATES  
Sabuco, Jean-Francois, Paris, FRANCE  
PATENT ASSIGNEE(S): AVENTIS PHARMACEUTICALS INC., Bridgewater, NJ, UNITED STATES, 08807-2854 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004102450	A1	20040527
APPLICATION INFO.:	US 2003-628093	A1	20030725 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-363196, filed on 28 Jul 1999, ABANDONED Continuation-in-part of Ser. No. WO 1999-US1682, filed on 27 Jan 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-72707P	19980127 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
LINE COUNT:	19006	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:114724 USPATFULL  
TITLE: N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa  
INVENTOR(S): Czekaj, Mark, Doylestown, PA, UNITED STATES  
Klein, Scott I., Collegeville, PA, UNITED STATES  
Pauls, Heinz W., Oakville, CANADA  
PATENT ASSIGNEE(S): AVENTIS PHARMA DEUTSCHLAND GMBH, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004087570	A1	20040506
APPLICATION INFO.:	US 2003-686871	A1	20031016 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-143190, filed on 10 May 2002, ABANDONED Continuation of Ser. No. WO 2000-EP10890, filed on 4 Nov 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-30540	19991223
	US 1999-164621P	19991110 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807	
NUMBER OF CLAIMS:	29	

EXEMPLARY CLAIM: 1  
LINE COUNT: 2768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to N-acylpyrrolidin-2-ylalkylbenzamidine derivatives which useful for inhibiting the activity of Factor Xa, by contacting said derivatives with a composition containing Factor Xa. The present invention is also directed to compositions containing said derivatives, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:89011 USPATFULL  
TITLE: PiperididinyI and N-amidinopiperidinyI derivatives  
INVENTOR(S): Klein, Scott I., Collegeville, PA, UNITED STATES  
Guertin, Kevin R., Verona, NJ, UNITED STATES  
PATENT ASSIGNEE(S): AVENTIS PHARMACEUTICALS INC., Bridgewater, NJ, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004067988	A1	20040408
APPLICATION INFO.:	US 2003-674480	A1	20030930 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-922906, filed on 6 Aug 2001, ABANDONED Division of Ser. No. US 1999-273618, filed on 22 Mar 1999, GRANTED, Pat. No. US 6277865		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79002P	19980323 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2317	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to a compound of formula I which is useful for inhibiting the activity of Factor Xa, by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:24677 USPATFULL  
TITLE: Ixodes scapularis tissue factor pathway inhibitor  
INVENTOR(S): Francischetti, Ivo M.B., Bethesda, MD, UNITED STATES  
Valenzuela, Jesus G., Gaithersburg, MD, UNITED STATES  
Ribeiro, Jose M. C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004018516	A1	20040129
APPLICATION INFO.:	US 2003-408166	A1	20030404 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2001-US42472, filed on 5		

Oct 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-240575P	20001005 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	29 Drawing Page(s)	
LINE COUNT:	6768	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Ixolaris, a novel protein with anticoagulant activity is described.  
Ixolaris can be isolated from the salivary glands of ticks or made by  
recombinant methods using various DNA expression techniques.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:272458 USPATFULL

TITLE: Minimal adenoviral vector

INVENTOR(S): Zhang, Wei-Wei, Libertyville, IL, UNITED STATES  
Alemany, Ramon, Grayslake, IL, UNITED STATES  
Dai, Yifan, Grayslake, IL, UNITED STATES  
Josephs, Steven, Grayslake, IL, UNITED STATES  
Balague, Cristina, Grayslake, IL, UNITED STATES  
Ayares, David, Blacksburgh, VA, UNITED STATES  
Schneiderman, Richard, Highland Park, IL, UNITED STATES

PATENT ASSIGNEE(S): GenStar Therapeutics Corp., San Diego, CA, UNITED  
STATES, 92121 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003192066	A1	20031009
APPLICATION INFO.:	US 2002-160078	A1	20020528 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-866403, filed on 30 May 1997, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1997-US10218	19970530
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MCDONNELL BOEHNNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606	
NUMBER OF CLAIMS:	112	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	54 Drawing Page(s)	
LINE COUNT:	4563	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is related to adenoviral (Ad) vectors and their  
applications in the field of genetic medicine, including gene transfer,  
gene therapy, and gene vaccination. More specifically, this invention is  
related to the Ad vectors that carry the minimal cis-element of the Ad  
genome (mini-Ad vector) and are capable of delivering transgenes and/or  
heterologous DNA up to 36 kb. The generation and propagation of the  
mini-Ad vectors require trans-complementation of a packaging-attenuated  
and replication-defective helper Ad (helper) in an Ad helper cell line.

This invention further comprises a methodology for generating a  
mini-adenoviral (mini-Ad) vector for use in gene therapy of hemophilia  
and animal test systems for in vivo evaluation of the Ad vectors. More

specifically, this invention describes factor VIII (FVIII) Ad vectors that only contain minimal cis-elements of the Ad genome (so called mini-Ad) and comprise a human FVIII cDNA with other supporting DNA elements up to 36 kb. The FVIII mini-Ad can be generated and preferentially amplified through the assistance of a packaging-attenuated helper Ad and a helper cell line. This invention also reports designs and methods for producing transgenic mouse models that can be used for in vivo testing the mini-Ad.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:244416 USPATFULL  
 TITLE: Protein complexes having factor VIII:C activity and production thereof  
 INVENTOR(S): Chapman, Barbara, Berkeley, CA, UNITED STATES  
 Burke, Rae Lyn, San Francisco, CA, UNITED STATES  
 Rasmussen, Mirella Ezban, Copenhagen, DENMARK  
 Mikkelsen, Jan Moller, Gentofte, DENMARK  
 PATENT ASSIGNEE(S): Chiron Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003170825	A1	20030911
APPLICATION INFO.:	US 2002-256849	A1	20020926 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-748062, filed on 22 Dec 2000, ABANDONED Continuation of Ser. No. US 1995-441943, filed on 16 May 1995, GRANTED, Pat. No. US 6228620 Division of Ser. No. US 1993-161770, filed on 3 Dec 1993, GRANTED, Pat. No. US 5595886 Continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, ABANDONED Continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, ABANDONED Continuation-in-part of Ser. No. US 1986-822989, filed on 27 Jan 1986, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	CHIRON CORPORATION, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1944		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an  $\alpha$ .sub.1-antitrypsin signal sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:220313 USPATFULL  
 TITLE: Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds  
 INVENTOR(S): Dankulich, William P., Collegeville, PA, UNITED STATES  
 McGarry, Daniel G., Bedminster, NJ, UNITED STATES  
 Burns, Christopher, Malvern, PA, UNITED STATES  
 Gallagher, Timothy F., Harleysville, PA, UNITED STATES

PATENT ASSIGNEE(S): Volz, Francis A., Neshanic Station, NJ, UNITED STATES  
Aventis Pharmaceuticals Inc., Bridgewater, NJ (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003153604	A1	20030814
APPLICATION INFO.:	US 2003-372499	A1	20030224 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-609103, filed on 30 Jun 2000, GRANTED, Pat. No. US 6541505 Continuation of Ser. No. WO 1999-US30623, filed on 22 Dec 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113710P	19981224 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7958	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to an (aminoiminomethyl or  
aminomethyl)benzoheteroaryl compound of formula I which is useful for  
inhibiting the activity of Factor Xa by combining said compound with a  
composition containing Factor Xa. The present invention is also directed  
to compositions containing compounds of the formula I, methods for their  
preparation, their use, such as in inhibiting the formation of thrombin  
or for treating a patient suffering from, or subject to, a disease state  
associated with a physiologically detrimental excess amount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:210031 USPATFULL  
TITLE: Sulfonic acid or sulfonylamino N-(heteroaralkyl)-  
azaheterocyclylamide compounds  
INVENTOR(S): Choi-Sledeski, Yong Mi, Collegeville, PA, United States  
Pauls, Henry W., Collegeville, PA, United States  
Barton, Jeffrey N., Philadelphia, PA, United States  
Ewing, William R., Downingtown, PA, United States  
Green, Daniel M., Ambler, PA, United States  
Becker, Michael R., Norristown, PA, United States  
Gong, Yong, Norristown, PA, United States  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Frankfurt, GERMANY,  
FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6602864	B1	20030805
APPLICATION INFO.:	US 1998-90492		19980603 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1997-US22406, filed on 3 Dec 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-33159P	19961213 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Coleman, Brenda	
LEGAL REPRESENTATIVE:	Parker, III, Raymond S., Newman, Irving	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	



NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)

LINE COUNT: 5493

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:134609 USPATFULL

TITLE: N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa

INVENTOR(S): Czekaj, Mark, Doylestown, PA, UNITED STATES  
Klein, Scott I, Collegeville, PA, UNITED STATES  
Pauls, Heinz W., Flemington, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092698	A1	20030515
APPLICATION INFO.:	US 2002-143190	A1	20020510 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-EP10890, filed on 4 Nov 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-30540	19991223
	US 1999-164621P	19991110 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2752	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to N-acylpyrrolidin-2-ylalkylbenzamidine derivatives which useful for inhibiting the activity of Factor Xa, by contacting said derivatives with a composition containing Factor Xa. The present invention is also directed to compositions containing said derivatives, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:106726 USPATFULL

TITLE: Pharmaceutical composition comprising factor VIIa and anti-TFPI

INVENTOR(S): Kjalke, Marianne, Copenhagen N, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073638	A1	20030417
APPLICATION INFO.:	US 2002-271926	A1	20021016 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2001-DK324, filed on 10 May		

2001, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2000-778	20000510
	DK 2000-771	20000510
	DK 2000-871	20000606
	US 2000-206194P	20000522 (60)
	US 206212P	(60)
	US 2000-212857P	20000620 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Reza Green, Esq., Novo Nordisk Pharmaceuticals, Inc., 100 College Road West, Princeton, NJ, 08540	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1264	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	The present invention relates to the use of factor VIIa and TFPI inhibitor in the treatment or prophylaxis of bleeding episodes or coagulative treatment.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 52 USPATFULL on STN

ACCESSION NUMBER:	2003:89407	USPATFULL
TITLE:	Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds	
INVENTOR(S):	Dankulich, William P., Collegeville, PA, United States McGarry, Daniel G., Bedminster, NJ, United States Burns, Christopher, Malvern, PA, United States Gallagher, Timothy F., Harleysville, PA, United States Volz, Francis A., Philadelphia, PA, United States	
PATENT ASSIGNEE(S):	Aventis Pharmaceuticals Inc., Bridgewater, NJ, United States (U.S. corporation)	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6541505	B1	20030401
APPLICATION INFO.:	US 2000-609103		20000630 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-US30623, filed on 22 Dec 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113710P	19981224 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Berch, Mark L.	
ASSISTANT EXAMINER:	Patel, Sudhaker B.	
LEGAL REPRESENTATIVE:	Parker, III, Raymond S., Newman, Irving	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	7892	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state	

associated with a physiologically detrimental excess amount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:338043 USPATFULL  
TITLE: Substituted (aminoiminomethyl or aminomethyl)  
dihydrobenzofurans and benzopyrans  
INVENTOR(S): Burns, Christopher J., Malvern, PA, UNITED STATES  
Dankulich, William P., Collegeville, PA, UNITED STATES  
McGarry, Daniel G., Bedminster, NJ, UNITED STATES  
Volz, Francis A., Neshanic Station, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193410	A1	20021219
	US 6599918	B2	20030729
APPLICATION INFO.:	US 2002-81113	A1	20020222 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-IB1562, filed on 12 Aug 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-24155	19991012
	US 1999-150767P	19990826 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D-303A, BRIDGEWATER, PA, 08807	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3825	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans that inhibit Factor Xa, pharmaceutical compositions comprising these compounds and their use for inhibiting Factor Xa or treating pathological conditions in a patient that may be ameliorated by administration of such compounds. This invention is also is also directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans which directly inhibit both Factor Xa and Factor IIa (thrombin), to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of simultaneously directly inhibiting both Factor Xa and Factor IIa (thrombin).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:201855 USPATFULL  
TITLE: Method for measuring antithrombin activity  
INVENTOR(S): Hoogendoorn, Hugh W., Ancaster, CANADA  
Duncan, Alexander, Decatur, GA, United States  
Morris, Michael J., South Bend, IN, United States  
PATENT ASSIGNEE(S): Affinity Biologicals, Inc., Hamilton, CANADA (non-U.S. corporation)  
R2 Diagnostics, Inc., South Bend, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6432658	B1	20020813
APPLICATION INFO.:	US 2000-661142		20000913 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		

PRIMARY EXAMINER: Leary, Louise N.  
LEGAL REPRESENTATIVE: Kolisch Hartwell Dickinson McCormack & Heuser  
NUMBER OF CLAIMS: 38  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)  
LINE COUNT: 500

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a one-stage method of measuring antithrombin (AT) activity in a sample. In the method, a diluted sample is mixed with AT-deficient plasma containing intrinsic coagulation enzymes, an AT augmenting compound such as heparin, a phospholipid and an activator of the contact phase of the intrinsic coagulation pathway. Following addition of calcium ions, coagulation time is measured and compared to a reference standard to determine the level of AT activity in the sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:181375 USPATFULL  
TITLE: Anticoagulant fusion protein anchored to cell membrane  
INVENTOR(S): Riesbeck, Kristian, Malmo, SWEDEN  
Dorling, Anthony, London, UNITED KINGDOM  
George, Andrew John Timothy, Surrey, UNITED KINGDOM  
Lechler, Robert Ian, London, UNITED KINGDOM  
PATENT ASSIGNEE(S): Imperial College Innovative Limited, London, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6423316	B1	20020723
	WO 9842850		19981001
APPLICATION INFO.:	US 2000-402515		20000202 (9)
	WO 1998-GB850		19980326
			20000202 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-6327	19970326
	GB 1997-20248	19970923
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Clark, Deborah J. R.	
ASSISTANT EXAMINER:	Chen, Shin-Lin	
LEGAL REPRESENTATIVE:	Darby & Darby	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	64 Drawing Figure(s); 36 Drawing Page(s)	
LINE COUNT:	1205	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:166378 USPATFULL  
TITLE: Minimal adenovirus mediated recombinant vaccine  
INVENTOR(S): Fang, Xiangming, San Diego, CA, UNITED STATES  
Gallichan, Scott, San Diego, CA, UNITED STATES  
Zhang, Wei-Wei, San Diego, CA, UNITED STATES  
Wong-Staal, Flossie, San Diego, CA, UNITED STATES  
Sauter, Sybille, Del Mar, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002088014	A1	20020704
APPLICATION INFO.:	US 2001-974206	A1	20011010 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-866403, filed on 30 May 1997, PENDING Continuation-in-part of Ser. No. US 1997-791218, filed on 31 Jan 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-658961, filed on 31 May 1996, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-239224P	20001010 (60)
	US 2000-241625P	20001019 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MCDONNELL BOEHNEN HULBERT & BERGHOFF, 300 SOUTH WACKER DRIVE, SUITE 3200, CHICAGO, IL, 60606	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	4062	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is related to adenoviral (Ad) vectors and their applications in the field of genetic medicine, including, but not limited to, gene vaccination, gene transfer, gene therapy, and the like. More specifically, this invention is related to the Ad vectors that carry the minimal cis-element of the Ad genome (minimal Ad vector) and are capable of delivering about 36 kb to about 38 kb of heterologous DNA. The generation and propagation of the minimal Ad vectors require trans-complementation of a packaging-attenuated and replication-defective helper Ad (helper) in an Ad helper cell line.

This invention further comprises minimal adenoviral vectors for use in the treatment or prevention of disease or other medical conditions, methodologies for generating such vectors and animal test systems for in vivo evaluation of such Ad vectors. More specifically, this invention describes HIV and/or HPV Ad vectors that contain minimal cis-elements of the Ad genome and comprise HIV and/or HPV nucleic acid sequence with other supporting and/or complementing nucleic acid elements up to about 36 kb to about 38 kb. The HIV and/or HPV minimal Ad may be generated and preferentially amplified through the assistance of a packaging-attenuated helper Ad and a helper cell line. This invention also discloses designs and methods for testing such minimal Ad vectors in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:85571 USPATFULL  
TITLE: 1-aroyle-piperidinyl benzamidines  
INVENTOR(S): Pauls, Heinz, Flemington, NJ, UNITED STATES  
Gong, Yong, Bridgewater, NJ, UNITED STATES  
Levell, Julian, Summit, NJ, UNITED STATES  
Astles, Peter, Kent, UNITED KINGDOM

Eastwood, Paul R., Essex, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002045613	A1	20020418
APPLICATION INFO.:	US 2001-841417	A1	20010424 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-18306	20000727
	US 2000-200066P	20000427 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AVENTIS PHARMACEUTICALS, INC., PATENTS DEPARTMENT, ROUTE 202-206, P.O. BOX 6800, BRIDGEWATER, NJ, 08807-0800	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3202	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	This invention relates to compounds of formula ##STR1##	

which inhibit Factor Xa or tryptase, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa or tryptase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 52 USPATFULL on STN  
ACCESSION NUMBER: 2002:27491 USPATFULL  
TITLE: Piperididinyl and N-amidinopiperidinyl derivatives  
INVENTOR(S): Klein, Scott I., Norristown, PA, UNITED STATES  
Guertin, Kevin R., Little Falls, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002016339	A1	20020207
APPLICATION INFO.:	US 2001-922906	A1	20010806 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-273618, filed on 22 Mar 1999, GRANTED, Pat. No. US 6277865		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79002P	19980323 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AVENTIS PHARMACEUTICALS, INC., PATENTS DEPARTMENT, ROUTE 202-206, P.O. BOX 6800, BRIDGEWATER, NJ, 08807-0800	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2328	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	This invention is directed to a compound of formula I which is useful for inhibiting the activity of Factor Xa, by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 22 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:22474 USPATFULL

TITLE: Sulfonic acid or sulfonylamino N-(heteroaralkyl)-  
azaheterocyclylamide compounds

INVENTOR(S): Choi-Sledeski, Yong Mi, Collegeville, PA, UNITED STATES  
Pauls, Heinz W., Collegeville, PA, UNITED STATES  
Barton, Jeffrey N., Philadelphia, PA, UNITED STATES  
Ewing, William R., Downingtown, PA, UNITED STATES  
Green, Daniel M., Ambler, PANAMA  
Becker, Michael R., Norristown, PA, UNITED STATES  
Gong, Yong, Norristown, PA, UNITED STATES  
Levell, Julian, Royersford, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002013310	A1	20020131
APPLICATION INFO.:	US 2001-918039	A1	20010730 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-453307, filed on 2 Dec 1999, GRANTED, Pat. No. US 6281227 Continuation-in-part of Ser. No. WO 1999-US12312, filed on 3 Jun 1999, UNKNOWN Continuation-in-part of Ser. No. US 1998-90492, filed on 3 Jun 1998, PENDING Continuation-in-part of Ser. No. WO 1997-US22406, filed on 3 Dec 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-33159P	19961213 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Synnestvedt & Lechner LLP, 2600 Aramark Tower, 1101 Market Street, Philadelphia, PA, 19107-2950	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7601	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2001:215074 USPATFULL

TITLE: Substituted N-[(aminoiminomethyl or  
aminomethyl)phenyl]propyl amides

INVENTOR(S): Klein, Scott I., Norristown, PA, United States  
Guertin, Kevin R., Little Falls, NJ, United States  
Spada, Alfred P., Lansdale, PA, United States  
Pauls, Heinz W., Collegeville, PA, United States  
Gong, Yong, Norristown, PA, United States  
McGarry, Daniel G., King of Prussia, PA, United States(4)

PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., Bridgewater, NJ,  
United States (U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 6323227 B1 20011127  
APPLICATION INFO.: US 1999-259528 19990226 (9)  
RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-US13550, filed on 26  
Jun 1998 Continuation-in-part of Ser. No. US 884405,  
now patented, Pat. No. US 6080767

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-9485P	19960102 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Gerstl, Robert	
LEGAL REPRESENTATIVE:	Newman, Irving	
NUMBER OF CLAIMS:	61	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4683	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to compounds of formula ##STR1##

which inhibit Factor Xa, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2001:173361 USPATFULL  
TITLE: Process for preparing tissue factor pathway inhibitor  
INVENTOR(S): Kamei, Shintaro, Kumamoto, Japan  
Kamikubo, Yuichi, Kumamoto, Japan  
Hamuro, Tsutomu, Kumamoto, Japan  
PATENT ASSIGNEE(S): Juridical Foundation the Chemo-Sero-Therapeutic  
Research Institute, Kumamoto-ken, Japan (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6300100	B1	20011009
APPLICATION INFO.:	US 1994-266542		19940628 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-188746	19930630
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Eyler, Yvonne	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	673	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In a process for preparing Tissue Factor Pathway Inhibitor (TFPI) by the genetically engineered technique by the use of a transformed animal cell wherein a DNA encoding human TFPI is introduced, the improvement which comprises culturing said transformed animal cell in a culture medium supplemented with a sulfated polysaccharide to protect an intact TFPI produced by said transformed animal cell from cleavage by proteases present in the culture medium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 52 USPATFULL on STN



ACCESSION NUMBER: 2001:142362 USPATFULL  
TITLE: Sulfonic acid sulfonylamino n-(heteroaralkyl)-  
azaheterocyclylamide compounds  
INVENTOR(S): Choi-Sledeski, Yong Mi, Collegeville, PA, United States  
Pauls, Heinz W., Collegeville, PA, United States  
Barton, Jeffrey N., Philadelphia, PA, United States  
Ewing, William R., Downingtown, PA, United States  
Green, Daniel M., Ambler, PA, United States  
Becker, Michael R., Norristown, PA, United States  
Gong, Yong, Norristown, PA, United States  
Levell, Julian, Royersford, PA, United States  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Frankfurt, Germany,  
Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6281227	B1	20010828
APPLICATION INFO.:	US 1999-453307		19991202 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1999-US12312, filed on 3 Jun 1999 Continuation-in-part of Ser. No. US 1998-90492, filed on 3 Jun 1998 Continuation-in-part of Ser. No. WO 1997-US22406, filed on 3 Dec 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-33159P	19961213 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Raymond, Richard L.	
ASSISTANT EXAMINER:	Truong, Tamthom N.	
LEGAL REPRESENTATIVE:	Parker, III, Raymond S., Butch, III, Peter J., Newman, Irving	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
LINE COUNT:	7432	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2001:139298 USPATFULL  
TITLE: Protein complexes having factor VIII:C activity and  
production thereof  
INVENTOR(S): Chapman, Barbara, Berkeley, CA, United States  
Burke, Rae Lyn, San Francisco, CA, United States  
Rasmussen, Mirella Ezban, Copenhagen, Denmark  
Mikkelsen, Jan Moller, Gentofte, Denmark  
PATENT ASSIGNEE(S): Chiron Corporation and Novo Nordisk A/S (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001016340	A1	20010823
APPLICATION INFO.:	US 2000-748062	A1	20001222 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-441943, filed on 16		

May 1995, GRANTED, Pat. No. US 6228620 Division of Ser. No. US 1993-161770, filed on 3 Dec 1993, GRANTED, Pat. No. US 5595886 Continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, ABANDONED Continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, ABANDONED Continuation-in-part of Ser. No. US 1986-822989, filed on 27 Jan 1986, ABANDONED

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 96662-8097  
NUMBER OF CLAIMS: 36  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1973

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an  $\alpha$ .sub.1-antitrypsin signal sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2001:136668 USPATFULL  
TITLE: PiperididinyI and N-amidinopiperidinyI derivatives  
INVENTOR(S): Klein, Scott I., Norristown, PA, United States  
Guertin, Kevin R., Verona, NJ, United States  
PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., Bridgewater, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6277865	B1	20010821
APPLICATION INFO.:	US 1999-273618		19990322 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-884405, filed on 27 Jun 1997, now patented, Pat. No. US 6080767		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-79002P	19980323 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Chang, Ceila	
LEGAL REPRESENTATIVE:	Parker, III, Raymond S., Newman, Irving, Butch, III, Peter J.	

NUMBER OF CLAIMS: 39  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2335

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to a compound of formula I which is useful for inhibiting the activity of Factor Xa, by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2001:67431 USPATFULL

TITLE: Protein complexes having factor VIII:C activity and production thereof

INVENTOR(S): Chapman, Barbara, Berkeley, CA, United States  
Burke, Rae Lyn, San Francisco, CA, United States  
Rasmussen, Mirella Ezban, Copenhagen, Denmark  
Mikkelsen, Jan Moller, Gentofte, Denmark

PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228620	B1	20010508
APPLICATION INFO.:	US 1995-441943		19950516 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-161770, filed on 3 Dec 1993, now patented, Pat. No. US 5595886 Continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, now abandoned Continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, now abandoned Continuation-in-part of Ser. No. US 1986-822989, filed on 27 Jan 1986, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Low, Christopher S. F.		
ASSISTANT EXAMINER:	Bugaisky, Gabriele E.		
LEGAL REPRESENTATIVE:	Robins, Roberta L., Guth, Joseph H., Blackburn, Robert P.		
NUMBER OF CLAIMS:	91		
EXEMPLARY CLAIM:	33		
LINE COUNT:	2140		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an  $\alpha$ .sub.1 -antitrypsin signal sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 29 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2001:51557 USPATFULL

TITLE: Vasoprotective recombinant adenovirus vector containing a human TFPI gene

INVENTOR(S): Zoldhelyi, Pierre, Bellaire, TX, United States  
Willerson, James T., Houston, TX, United States

PATENT ASSIGNEE(S): Texas Heart Institute, Houston, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6214333	B1	20010410
APPLICATION INFO.:	US 1998-13366		19980126 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-51887P	19970708 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Guzo, David	
LEGAL REPRESENTATIVE:	McDaniel & Associates, P.C., McDaniel, C. Steven, Hall, Elizabeth R.	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	1537	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A recombinant adenoviral vector encoding the human tissue factor pathway inhibitor (TFPI) gene is disclosed which is useful for transduction of vascular smooth muscle cells at a selected blood vessel site to provide local vascular expression of TFPI. A method of using the transduced hTFPI cDNA as an in vivo antithrombotic agent to provide localized production of hTFPI for protecting an at-risk site against thrombus deposition is also disclosed. Gene therapy using the new TFPI expression vector is also expected to deter the development of chronic vascular stenosis in blood vessels (arteries, veins, arteriovenous shunts, and endovascular grafts) and deterring intimal hyperplasia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 30 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2000:146550 USPATFULL  
 TITLE: Substituted intermediate compounds for the preparation of n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides  
 INVENTOR(S): Klein, Scott I., Norristown, PA, United States  
 Guertin, Kevin R., Verona, NJ, United States  
 Spada, Alfred P., Lansdale, PA, United States  
 PATENT ASSIGNEE(S): Aventis Pharmaceuticals Products Inc., Bridgewater, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6140504		20001031
APPLICATION INFO.:	US 2000-499335		20000204 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 884405		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-9485P	19960102 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Gerstl, Robert	
LEGAL REPRESENTATIVE:	Newman, Irving, Butch, Peter	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1,2	
LINE COUNT:	2891	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2000:80775 USPATFULL  
 TITLE: Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides  
 INVENTOR(S): Klein, Scott I., Norristown, PA, United States

PATENT ASSIGNEE(S): Guertin, Kevin R., Little Falls, NJ, United States  
Spada, Alfred P., Lansdale, PA, United States  
Aventis Pharmaceuticals Products Inc., Collegeville,  
PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6080767		20000627
APPLICATION INFO.:	US 1997-884405		19970627 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1996-US20770, filed on 23 Dec 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-9485P	19960102 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Gerstl, Robert	
LEGAL REPRESENTATIVE:	Oehler, Ross J.	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3455	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compounds according to the invention are substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides of formula I herein which exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are Factor Xa inhibitors. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, methods for their preparation and their use, which are for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2000:57741 USPATFULL  
TITLE: Protein complexes having Factor VIII:C activity and production thereof  
INVENTOR(S): Chapman, Barbara, Berkeley, CA, United States  
Burke, Rae Lyn, San Francisco, CA, United States  
Rasmussen, Mirella Ezban, Copenhagen, Denmark  
Mikkelsen, Jan Moller, Gentofte, Denmark  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6060447		20000509
APPLICATION INFO.:	US 1995-441935		19950516 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-266170, filed on 27 Jun 1994, now patented, Pat. No. US 5789203 which is a continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, now abandoned which is a continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, now abandoned which is a continuation-in-part of Ser. No. US 1996-822989, filed on 27 Jan 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Patterson, Jr., Charles L.		
LEGAL REPRESENTATIVE:	Robins, Roberta L., Guth, Joseph H., Blackburn, Robert		

P.  
NUMBER OF CLAIMS: 35  
EXEMPLARY CLAIM: 1  
LINE COUNT: 2096

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an  $\alpha$ .sub.1 -antitrypsin signal sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 33 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2000:27989 USPATFULL

TITLE: Substituted sulfonic acid N-  
[(aminoiminomethyl)phenylalkyl]-azaheterocyclamide  
compounds

INVENTOR(S): Ewing, William R., Downingtown, PA, United States  
Becker, Michael R., Norristown, PA, United States  
Choi-Sledeski, Yong Mi, Collegeville, PA, United States  
Pauls, Heinz W., Collegeville, PA, United States  
McGarry, Daniel G., King of Prussia, PA, United States  
Davis, Roderick S., West Chester, PA, United States  
Spada, Alfred P., Lansdale, PA, United States

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville,  
PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6034093		20000307
APPLICATION INFO.:	US 1998-130336		19980806 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1997-US22414, filed on 1 Dec 1997 which is a continuation-in-part of Ser. No. US 1996-761414, filed on 6 Dec 1996, now patented, Pat. No. US 5731315, issued on 24 Mar 1998 which is a continuation-in-part of Ser. No. WO 1996-US9816, filed on 7 Jun 1996 which is a continuation-in-part of Ser. No. US 1995-481024, filed on 7 Jun 1995, now patented, Pat. No. US 5612353, issued on 18 Mar 1997 And a continuation-in-part of Ser. No. WO US9722414 which is a continuation-in-part of Ser. No. US 1997-976034, filed on 21 Nov 1997 which is a continuation of Ser. No. WO US9609816 which is a continuation-in-part of Ser. No. US 481024		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Davis, Zinna Northington		
LEGAL REPRESENTATIVE:	Oehler, Rose J.		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
LINE COUNT:	4980		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions

containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 34 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1999:117489 USPATFULL

TITLE: Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminominomethyl)phenylalkyl]-azaheterocyclylamide compounds

INVENTOR(S): Ewing, William R., Downingtown, PA, United States  
Becker, Michael R., Norristown, PA, United States  
Pauls, Henry W., Collegeville, PA, United States  
Cheney, Daniel L., Collegeville, PA, United States  
Mason, Jonathan Stephen, Phoenixville, PA, United States  
Spada, Alfred P., Lansdale, PA, United States  
Choi-Sledeski, Yong Mi, Collegeville, PA, United States  
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5958918		19990928
APPLICATION INFO.:	US 1997-976034		19971121 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1996-US9816, filed on 7 Jun 1996 which is a continuation-in-part of Ser. No. US 1995-481024, filed on 7 Jun 1995, now patented, Pat. No. US 5612353		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Davis, Zinna Northington		
LEGAL REPRESENTATIVE:	Parker, III, Raymond S.		
NUMBER OF CLAIMS:	57		
EXEMPLARY CLAIM:	1		
LINE COUNT:	9289		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 35 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1999:30937 USPATFULL

TITLE: Factor VIIa inhibitors from Kunitz domain proteins

INVENTOR(S): Dennis, Mark S., San Carlos, CA, United States

Lazarus, Robert A., Milbrae, CA, United States

PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5880256		19990309
APPLICATION INFO.:	US 1995-399115		19950303 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-206310, filed  
on 4 Mar 1994, now abandoned  
DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Jacobson, Dian C.  
LEGAL REPRESENTATIVE: Kubinec, Jeffrey S.  
NUMBER OF CLAIMS: 67  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 7 Drawing Page(s)  
LINE COUNT: 2832

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A potent serine protease inhibitor capable of inhibiting Factor VIIa,  
Factor XIa, plasma kallikrein, or plasmin is provided. The inhibitor is  
provided in a pharmaceutical composition for treatment of diseases where  
inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is  
indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 36 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1999:12902 USPATFULL  
TITLE: Factor VIIa inhibitors from kunitz domain proteins  
INVENTOR(S): Dennis, Mark S., San Carlos, CA, United States  
Lazarus, Robert A., Millbrae, CA, United States  
PATENT ASSIGNEE(S): Genentech, Inc., San Francisco, CA, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5863893		19990126
APPLICATION INFO.:	US 1995-398628		19950303 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-206310, filed on 4 Mar 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jacobson, Dian C.		
LEGAL REPRESENTATIVE:	Kubinec, Jeffrey S.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	2603		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A potent serine protease inhibitor capable of inhibiting Factor VIIa,  
Factor XIa, plasma kallikrein, or plasmin is provided. The inhibitor is  
provided in a pharmaceutical composition for treatment of diseases where  
inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is  
indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 37 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1998:157308 USPATFULL  
TITLE: Pre-formed anticoagulant heparin/TFPI complexes  
INVENTOR(S): Wun, Tze-Chein, St. Louis, MO, United States  
PATENT ASSIGNEE(S): G. D. Searle & Co., Chicago, IL, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849703		19981215
APPLICATION INFO.:	US 1996-661240		19960610 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-453937, filed on 30 May 1995 which is a continuation-in-part of Ser. No. US 1993-166186, filed on 13 Dec 1993, now abandoned		



which is a continuation of Ser. No. US 1990-573083,  
filed on 27 Aug 1990, now abandoned

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Sayala, Chhaya D.  
LEGAL REPRESENTATIVE: Meyer, Scott J.  
NUMBER OF CLAIMS: 17  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 8 Drawing Page(s)  
LINE COUNT: 798

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pre-formed anticoagulant heparin/TFPI complex which consists of a  
weight ratio of at least 1.25 parts of heparin to one part of TFPI and  
its use in inhibiting blood coagulation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 38 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1998:138687 USPATFULL  
TITLE: Factor VIIa inhibitors from Kunitz domain proteins  
INVENTOR(S): Dennis, Mark S., San Carlos, CA, United States  
Lazarus, Robert A., Millbrae, CA, United States  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834244		19981110
APPLICATION INFO.:	US 1995-398010		19950303 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-206310, filed on 4 Mar 1994		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Jacobson, Dian C.  
LEGAL REPRESENTATIVE: Kubinec, Jeffrey S.  
NUMBER OF CLAIMS: 17  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)  
LINE COUNT: 2676

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A potent serine protease inhibitor capable of inhibiting Factor VIIa,  
Factor XIa, plasma kallikrein, or plasmin is provided. The inhibitor is  
provided in a pharmaceutical composition for treatment of diseases where  
inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is  
indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 39 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1998:135168 USPATFULL  
TITLE: Process for purifying factor VIII  
INVENTOR(S): Almstedt, Annelie, Sp.ang.nga, Sweden  
Sandberg, Helena, Bromma, Sweden  
Smeds, Anna-Lisa, Sollentuna, Sweden  
Wrangel, Maria, Vallingby, Sweden  
Ostlin, Anna, Stockholm, Sweden  
PATENT ASSIGNEE(S): Pharmacia & Upjohn AB, Stockholm, Sweden (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5831026		19981103
	WO 9615150		19960523
APPLICATION INFO.:	US 1997-809756		19970530 (8)

WO 1995-SE1351

19951114

19970530 PCT 371 date

19970530 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1994-3915	19941114
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Tsang, Cecilia J.	
ASSISTANT EXAMINER:	Mohamed, Abdel A.	
LEGAL REPRESENTATIVE:	Dinsmore & Shohl LLP	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	867	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for reducing degradation of recombinant coagulation factor VIII caused by metal-dependent proteases requiring Zn.sup.2+ for activity or containing Zn.sup.2+ as an integral part of their structure comprises adding an inhibitor of Zn.sup.2+ dependent proteases to a recombinant factor VIII solution. The recombinant factor VIII solution is obtained after harvesting a conditioned medium from a cell culture used for producing the recombinant coagulation factor VIII. The inhibitor is selected from complexing agents with a stronger affinity for the Zn.sup.2+ ion of the protease than for the ion or ions stabilizing the factor VIII molecule, and compounds structurally related to the natural substrate of the protease and containing an electronegative moiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 40 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1998:98974 USPATFULL  
TITLE: Factor VIIa inhibitors from Kunitz domain proteins  
INVENTOR(S): Lazarus, Robert A., Milbrae, CA, United States  
Dennis, Mark S., San Carlos, CA, United States  
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795954		19980818
APPLICATION INFO.:	US 1994-206310		19940304 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jacobson, Dian C.		
LEGAL REPRESENTATIVE:	Kubinec, Jeffrey S.		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	2051		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, and plasmin is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1998:91834 USPATFULL  
TITLE: Protein complexes having factor VIII:C activity and production thereof

INVENTOR(S): Chapman, Barbara, Berkeley, CA, United States  
 Burke, Rae Lyn, San Francisco, CA, United States  
 Rasmussen, Mirella Ezban, Copenhagen, Denmark  
 Mikkelsen, Jan Moller, Gentofte, Denmark  
 PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
 Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5789203		19980804
APPLICATION INFO.:	US 1994-266170		19940627 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, now abandoned which is a continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-822989, filed on 27 Jan 1986, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jacobson, Dian C.		
LEGAL REPRESENTATIVE:	Barovsky, Kenneth, Robins, Roberta, Blackburn, Robert P.		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1898		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an  $\alpha$ .sub.1 -antitrypsin signal sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 42 OF 52 USPATFULL on STN

ACCESSION NUMBER: 1998:31022 USPATFULL  
 TITLE: Substituted sulfonic acid n-  
 [(aminoiminomethyl)phenylalkyl]-azaheterocyclamide compounds

INVENTOR(S): Ewing, William R., Downingtown, PA, United States  
 Becker, Michael R., Norristown, PA, United States  
 Choi-Sledeski, Yong Mi, Collegeville, PA, United States  
 Pauls, Heinz W., Collegeville, PA, United States  
 McGarry, Daniel G., King of Prussia, PA, United States  
 Davis, Roderick S., West Chester, PA, United States  
 Spada, Alfred P., Lansdale, PA, United States  
 PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5731315		19980324
APPLICATION INFO.:	US 1996-761414		19961206 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-481024, filed on 7 Jun 1995, now patented, Pat. No. US 5612353		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Northington-Davis, Zinna  
LEGAL REPRESENTATIVE: Parker, III, Raymond S., Savitzky, Martin F.  
NUMBER OF CLAIMS: 44  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3981

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 43 OF 52 USPATFULL on STN

ACCESSION NUMBER: 97:63992 USPATFULL  
TITLE: Methods and compositions for inhibition of hepatic clearance of tissue factor pathway inhibitor  
INVENTOR(S): Schwartz, Alan L., Clayton, MO, United States  
Warshawsky, Ilka, St. Louis, MO, United States  
Broze, George J., Ladue, MO, United States  
PATENT ASSIGNEE(S): Jewish Hospital of St. Louis, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5650391		19970722
APPLICATION INFO.:	US 1994-216593		19940321 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Allen, Marianne P.		
ASSISTANT EXAMINER:	Gucker, Stephen		
LEGAL REPRESENTATIVE:	Bennett, Dennis A.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	788		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention discloses methods and compositions for inhibiting the hepatic clearance of Tissue Factor Pathway Inhibitor (TFPI) using receptor-associated protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 44 OF 52 USPATFULL on STN

ACCESSION NUMBER: 97:33783 USPATFULL  
TITLE: Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time  
INVENTOR(S): Worsaae, Helle, Gentofte, Denmark  
Rasmussen, Frank W., Valby, Denmark  
Rasmussen, Mirella E., Copenhagen, Denmark  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5622988		19970422
APPLICATION INFO.:	US 1995-405336		19950316 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-95785, filed on 22 Jul 1993, now patented, Pat. No. US 5409951 which		

is a continuation-in-part of Ser. No. US 1991-714107,  
filed on 11 Jun 1991, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1990-1461	19900615
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chan, Nicky	
LEGAL REPRESENTATIVE:	Zelson, Esq., Zelson T., Agris, Esq., Cheryl H.	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	650	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the use of compounds of formula I  
##STR1## wherein R.sup.1 is independently hydrogen, hydroxy, alkyl with  
1 to 6 carbon atoms, acyloxy groups with 1 to 6 carbon atoms, alkyloxy  
with 1 to 6 carbon atoms or from 1 to 5 sugar moieties; and R.sup.2 is  
independently hydrogen, or alkyl with 1 to 6 carbon atoms, in the  
reduction of coagulation time in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 45 OF 52 USPATFULL on STN

ACCESSION NUMBER: 97:20645 USPATFULL  
TITLE: Process for producing a coagulation active complex of  
factor VIII fragments  
INVENTOR(S): Nordfang, Ole, Hiller.o slashed.d, Denmark  
Rasmussen, Mirella E., Copenhagen, Denmark  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5610278		19970311
APPLICATION INFO.:	US 1995-383034		19950203 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-65702, filed on 21 May 1993 which is a continuation of Ser. No. US 1992-869885, filed on 14 Apr 1992, now abandoned which is a continuation of Ser. No. US 1989-298465, filed on 18 Jan 1989, now abandoned which is a division of Ser. No. US 1988-162323, filed on 23 Feb 1988, now abandoned which is a continuation-in-part of Ser. No. US 1986-932923, filed on 19 Nov 1986, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1986-2957	19860624
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Jacobson, Dian C.	
LEGAL REPRESENTATIVE:	Zelson, Esq., Steve T., Argis, Esq., Cheryl H.	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	325	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A coagulation active complex of Factor VIII fragments is produced by  
causing coagulation inactive FVIII heavy chain to react with coagulation  
inactive FVIII light chain in the presence of a complex forming agent.  
Thus, FVIII-HC and FVIII-LC are converted to coagulation active FVIII  
complex in the presence of divalent metal ions, such as Mn.sup.2+,  
Ca.sup.2+ or C.sup.2+, or a component of the pro-thrombin complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 46 OF 52 USPATFULL on STN

ACCESSION NUMBER: 97:20404 USPATFULL

TITLE: Method of producing proteins with FVIII activity and/or FVIII derivatives

INVENTOR(S): Rasmussen, Poul B., Hellerup, Denmark  
Nordfang, Ole, Hillerod, Denmark

PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5610033		19970311
APPLICATION INFO.:	US 1994-320773		19941011 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-877347, filed on 30 Apr 1992, now abandoned which is a continuation of Ser. No. US 1990-514072, filed on 25 Apr 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ziska, Suzanne E.		
LEGAL REPRESENTATIVE:	Zelson, Esq., Steve T., Agris, Esq., Cheryl H.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	289		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In a process for producing proteins with FVIII activity and FVIII derivatives by in vitro culturing of mammalian cells, the culturing is carried out at temperatures below 32° C. and the culturing times used are below 24 hours.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 47 OF 52 USPATFULL on STN

ACCESSION NUMBER: 97:5867 USPATFULL

TITLE: Protein complexes having Factor VIII:C activity and production thereof

INVENTOR(S): Chapman, Barbara, Berkeley, CA, United States  
Burke, Rae L., San Francisco, CA, United States

PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5595886		19970121
APPLICATION INFO.:	US 1993-161770		19931203 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-652099, filed on 7 Feb 1991, now abandoned which is a continuation-in-part of Ser. No. US 1987-51916, filed on 19 May 1987, now abandoned which is a continuation-in-part of Ser. No. US 1986-822989, filed on 27 Jan 1986, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jacobson, Dian C.		
LEGAL REPRESENTATIVE:	Reed & Robins, Blackburn, Robert P.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1532		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB DNA constructs encoding human Factor VIII:C protein are disclosed. In particular, the DNA construct contains a nucleotide sequence that encodes a first polypeptide homologous to the A domain of human Factor

VIII:C linked to a second polypeptide homologous to the C domain of human Factor VIII:C by a polypeptide spacer that comprises a peptide homologous to a human Ig heavy chain hinge region. Recombinant methods for producing human Factor VIII:C protein are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 48 OF 52 USPATFULL on STN

ACCESSION NUMBER: 96:106467 USPATFULL  
TITLE: Human Kunitz-type protease inhibitor variant  
INVENTOR(S): Norris, Fanny, Hellerup, Denmark  
Norris, Kjeld, Hellerup, Denmark  
Bj.o slashed.rn, S.o slashed.ren E., Lyngby, Denmark  
Petersen, Lars C., H.o slashed.rsholm, Denmark  
Olsen, Ole H., Br.o slashed.nsh.o slashed.j, Denmark  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5576294		19961119
APPLICATION INFO.:	US 1994-321658		19941012 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-21610, filed on 22 Feb 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1992-DK1	19920107
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wax, Robert A.	
ASSISTANT EXAMINER:	Kim, Hyosuk	
LEGAL REPRESENTATIVE:	Zelson, Steve T., Lambiris, Elias J.	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	1204	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Variant of human Kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI), the variant comprising the following amino acid sequence ##STR1## wherein Xaa at position 1 is H or a naturally occurring amino acid residue except Cys, each Xaa at positions 2-5 is independently a naturally occurring amino acid residue except Cys or is absent, each Xaa at positions 14, 16, 18, 19, 20, 21, 22, 23, 37, 42, 43, 44, and 49 independently a naturally occurring amino acid except Cys, each Xaa at positions 61, 62, 63, and 64 is independently a naturally occurring amino acid except Cys or is absent, and Xaa at position 65 is OH or a naturally occurring amino acid except Cys, with the proviso that at least one of the amino acid residues designated Xaa is different from the amino acid residue of the native sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 49 OF 52 USPATFULL on STN

ACCESSION NUMBER: 96:70540 USPATFULL  
TITLE: Process for producing a coagulation active complex of factor VIII fragments  
INVENTOR(S): Nordfang, Ole, Hillerod, Denmark  
Rasmussen, Mirella E., Copenhagen, Denmark  
PATENT ASSIGNEE(S): Novo Nordisk A/S, Novo Alle, Denmark (non-U.S.  
corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5543502 19960806  
 APPLICATION INFO.: US 1995-383541 19950203 (8)  
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-92658, filed on 14 Jul 1993, now abandoned which is a continuation of Ser. No. US 1992-956445, filed on 2 Oct 1992, now abandoned which is a continuation of Ser. No. US 1992-835100, filed on 11 Feb 1992, now abandoned which is a continuation of Ser. No. US 1988-162323, filed on 23 Feb 1988, now abandoned which is a continuation-in-part of Ser. No. US 1986-932923, filed on 19 Nov 1986, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1986-2957	19860624
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Fleisher, Mindy	
ASSISTANT EXAMINER:	Degen, Nancy J.	
LEGAL REPRESENTATIVE:	Zelson, Esq., Steve T., Agris, Esq., Cheryl H.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	399	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A coagulation active complex of Factor VIII fragments is produced by causing a coagulation inactive FVIII heavy chain to react with a coagulation inactive FVIII light chain in the presence of a complex forming agent. Thus, FVIII-HC and FVIII-LC are converted to coagulation active FVIII complex in the presence of metal ions, such as Mn.sup.2+, Ca.sup.2+, or Co.sup.2+ or a component of the prothrombin complex or a substance having reactivity to compounds containing the group --SH and/or --S--S.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 50 OF 52 USPATFULL on STN  
 ACCESSION NUMBER: 95:1518 USPATFULL  
 TITLE: Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast  
 INVENTOR(S): Petersen, Jens G. L., Valby, Denmark  
 Nordfang, Ole J., Hilleroed, Denmark  
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5378614		19950103
APPLICATION INFO.:	US 1993-26145		19930302 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-828920, filed on 27 Jan 1992, now patented, Pat. No. US 5312736		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1989-4080	19890818
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Draper, Garnette D.	
ASSISTANT EXAMINER:	Fitzgerald, David L.	
LEGAL REPRESENTATIVE:	Zelson, Steve T., Lowney, Karen A.	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	835	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



AB A method for making TFPI analogues lacking part of the C-terminal end of the native TFPI molecule is described by cultivation of a yeast strain transformed with an expression vector containing a DNA sequence encoding such TFPI analogues. The TFPI analogues will at least contain the two first Kunitz domains and lack the third Kunitz domain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 51 OF 52 USPATFULL on STN

ACCESSION NUMBER: 89:39058 USPATFULL

TITLE: Preparation for the treatment of hemophilia A inhibitor patients and a process for producing such a preparation

INVENTOR(S): Nordfang, Ole, Selskovvej 6, DK-3400 Hillerod, Denmark  
Rasmussen, Mirella E., Abildgaardsgade 24, DK-2100 Copenhagen 0, Denmark

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4831119		19890516
	WO 8602838		19860522
APPLICATION INFO.:	US 1986-881687		19860620 (6)
	WO 1985-DK105		19851105
			19860620 PCT 371 date
			19860620 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1984-5253	19841105
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Welsh, Maurice J.	
ASSISTANT EXAMINER:	Nutter, Nathan M.	
LEGAL REPRESENTATIVE:	Ladas & Parry	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	590	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A preparation for the treatment of hemophilia A inhibitor patients contains a protein or peptide having a specific Factor VIII:Cag activity of at least 0.5, preferably at least 1 VIII:Cag unit per mg protein, the ratio between the VIII:Cag activity and the VIII:C procoagulant activity being greater than 5:1, preferably greater than 10:1. A fragment of Factor VI-II:C, which displays a doublet of a molecular weight of 80/77 kD in electrophoresis, is reactive hemophilia A inhibitor antibodies and has VIII:Cag activity. This fragment and more low-molecular fragments of Factor VIII:C are capable of neutralizing the coagulation inhibiting effect of all tested antibodies. Such fragments can therefore be used as active component in preparations for providing immunotolerance towards Factor VIII:C in high-dose treatment of inhibitor patients. The peptides are moreover useful as an immunosorbent in specific extracorporeal adsorption treatment of inhibitor patients. The inhibitor reactive peptides can e.g. be recovered from plasma fractions by affinity chromatography, hydrophobic interaction chromatography or cation exchange or they may be biosynthetically and recovered in a similar manner.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 52 OF 52 USPAT2 on STN

ACCESSION NUMBER: 2002:338043 USPAT2

TITLE: Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans

INVENTOR(S): Burns, Christopher J., Malvern, PA, United States

## PATENT ASSIGNEE(S):

Dankulich, William P., Collegeville, PA, United States  
McGarry, Daniel G., Bedminster, NJ, United States  
Volz, Francis A., Neshanic Station, NJ, United States  
Aventis Pharmaceuticals Inc., Bridgewater, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6599918	B2	20030729
APPLICATION INFO.:	US 2002-81113		20020222 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-IB1562, filed on 12 Aug 2000		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-24155	19991012
	US 1999-150767P	19990826 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Solola, Taofiq	
LEGAL REPRESENTATIVE:	Parker, III, Raymond S.	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	3793	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans that inhibit Factor Xa, pharmaceutical compositions comprising these compounds and their use for inhibiting Factor Xa or treating pathological conditions in a patient that may be ameliorated by administration of such compounds. This invention is also is also directed to substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans which directly inhibit both Factor Xa and Factor IIa (thrombin), to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds and to a method of simultaneously directly inhibiting both Factor Xa and Factor IIa (thrombin).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>